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SUMMARY 
The B-aggressive lymphoma protein and ADP-ribosyltransferase BAL1/ARTD9 is a 
nucleocytoplasmic shuttling protein and belongs to the intracellular diphtheria toxin-
related ARTD family (former PARPs) of mono- and polymerizing-ADP-
ribosyltransferases. Expression of BAL1/ARDT9 is highly induced in most cells upon 
IFN!, IFN"/# or LPS treatment. BAL1/ARDT9 has been initially identified as a 
potential risk-related gene product in aggressive diffuse large B-cell lymphoma 
(DLBCL). BAL1/ARDT9 is constitutively expressed in a subset of aggressive 
chemoresistant high-risk subtypes of DLBCL associated with an active but ineffective 
IFN! mediated host inflammatory response (HR).  A recent study provided 
preliminary evidence that BAL1/ARDT9 might be associated with lymphocyte 
migration. BAL1/ARDT9 has been proposed to promote the dissemination of 
malignant B cells in high-risk DLBCL and thus a potential novel target for 
chemotherapy. Our preliminary studies investigating the role of B-aggressive 
lymphoma protein and ADP-ribosyltransferase BAL1/ARTD9 in DLBCL and 
metastatic prostate cancer provide preliminary evidence that BAL1/ARDT9 is directly 
involved in modulation of IFN!- dependent signaling and gene expression in HR-
DLBCL and prostate cancers.  
We found that BAL1/ARTD9 is constitutively expressed in DLBCL associated with 
constitutively active STAT1 signaling. Our results indicate that STAT1 could act as 
an oncogene in high-risk DLBCL with an active host inflammatory response. This 
activity is at least partially mediated by the B-aggressive lymphoma protein and ADP-
ribosyltransferase BAL1/ARTD9. We could identify BAL1/ARDT9 as a novel IFN!-
dependent repressor of the tumor suppressor IRF1 and transcriptional activator of 
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BCL6 and IRF2. Strikingly, BAL1/ARDT9 inhibits IRF1 at the level of expression 
and nuclear translocation. Moreover we could show that BAL1/ARTD9 interacts with 
both STAT1" and STAT1# through its macro domains in a mono-ADP-ribosylation 
dependent manner. As a consequence, BAL1/ARTD9 represses IRF1/p53 dependent 
pro-apoptotic pathways and mediates proliferation and survival in high-risk diffuse 
large B-cell lymphomas. A similar observation was made in p53 negative metastatic 
prostate cancers cell lines suggesting that BAL1/ARTD9 negatively regulates IFN!-
dependent tumor suppressor genes and contributes to cell survival and tumor growth 
in different types of cancers. 
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ZUSAMMENFASSUNG 
Das B-aggressive Lymphoma (BAL) Protein-1, auch ADP-ribosyltransferase ARTD9 
genannt gehört zu einer Enzymfamilie von intrazellulären Diphtheria-Toxin-ähnlichen 
mono- und poly-ADP-ribosyltransferasen (ARTDs). BAL1/ARTD9 ist sowohl im 
Zellkern als auch Zytoplasma der Zelle lokalisiert.  Die Expression von 
BAL1/ARTD9 ist sehr stark kontrolliert und wird hauptsächlich nach Stimulation der 
Zellen mit Interferonen (IFN!, IFN"/#) und LPS aufreguliert. BAL1/ARDT9 wurde 
kürzlich als potentieller Risikofaktor in hochmalignen diffus großzelligen B-Zell-
Lymphomen (DLBCL) identifiziert. Diese Studien zeigten, dass BAL1/ARDT9 in 
chemoresistenten Hochrisiko-DLBCL Formen konstitutiv überexprimiert ist welche 
eine aktive aber ineffektive IFN! abhängige Immunantwort auslösen (HR-DLBCL). 
Diese Studien schlugen vor, dass BAL1/ARDT9 für die Zellmigration von B-
Lymphozyten und Lymphomazellen verantwortlich sein könnte. 
Unsere eigenen Studien deuten darauf hin, dass BAL1/ARDT9 direkt in der 
Regulierung von IFN! abhängigen Signalkaskaden und Genexpressionsprogrammen 
involviert ist, sowohl in DLBCL als auch in Prostatakrebs. Konstitutive 
Überexpression von BAL1/ARDT9 in HR-DLBCL und Prostatakrebs korreliert direkt 
mit konstitutiven und IFN!-abhängigen STAT1 Aktivitäten. Unsere Studien zeigen 
weiter, dass STAT1 in diesen Krebsformen nicht als Tumorsuppressor sondern 
vielmehr als BAL1/ARDT9 abhängiges Onkogenprodukt wirkt. Wir konnten 
BAL1/ARDT9 als IFN! abhängigen Onkogen-ähnlichen Faktor in DLBCL 
identifizieren der einerseits den Tumorsupressor IRF1 inhibiert und gleichzeitig die 
Expression der beiden Onkogenprodukte BCL6 und IRF2 in aggressiven DLBCL 
Formen stimuliert. Bemerkenswerterweise inhibiert BAL1/ARDT9 nicht nur die 
transkriptionelle Aufregulierung von IRF1 sondern auch die Translokation von IRF1 
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in den Zellkern. Unsere Studien zeigen darüber hinaus, dass BAL1/ARDT9 mit 
beiden STAT1 Isoformen STAT1" und STAT1# interagieren kann. Die Interaktion 
findet über die Makro-Domänen von BAL1/ARDT9 statt und wird durch ADP-
ribosylierung positiv reguliert. Die Inhibierung von IRF1 und Aufregulierung von 
BCL6 respektive IRF2 durch BAL1/ARDT9 führt nun dazu dass die pro-
apoptotischen und anti-proliferativen Kaskaden unterdrückt werden. Als Konsequenz 
fördert BAL1/ARDT9 die Proliferation und das Überleben von chemoresistenten 
Hochrisiko-Formen von DLBCL und Prostatakrebs. 
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INTRODUCTION 
CHAPTER1.  
1.1 Diffuse large B-cell lymphoma (DLBCL) 
Diffuse large B-cell lymphoma (DLBCL) is a clinically and genetic heterogeneous 
non-Hodgkin's subtype of B-cell lymphoma and the most common lymphoid 
malignancy in adults, accounting for roughly 35% of all lymphoma cases worldwide 
(1-3). In the Western world, nearly 90% of aggressive mature B-cell lymphomas are 
identified as DLBCL (4, 5). This heterogeneous disease takes an aggressive and fatal 
clinical course with a median survival of less than one year if left untreated. Since the 
1970s, overall incidence of non-Hodgkin lymphomas has increased about 45% in 
Switzerland, with an annual incidence of approximately 1500 cases per year, 
corresponding to an incidence of 4% of the total cases of new cancers in Switzerland 
per year (53.1% men) and (46.9% women) and to a mortality rate of 3.2% per year of 
total cancer death rate (http://www.krebsforschung.ch) (4, 5). Although more than 
half of DLBLC patients succumb to the disease, the rest of them can be cured with 
current multi-agent chemo-, radio- and/or immunotherapeutic regimens, representing 
one of the successes of modern cancer therapy (1-3, 6). However, over the last four 
decades, mortality from DLBCL increased in most developed areas of the world. 
DLBCL were among the few neoplasms showing consistent upward trends in North 
America and Europe over the last few decades (4, 5, 7). 
Several genetic abnormalities including aberrant somatic hypermutation and 
translocations (i.e. BCL2, c-MYC or BCL6) and overexpression of BCL2/Rel/MYC, 
constitutive activation of STAT6, BCL2 and/or NF-!B pathways have been identified 
in DLBCLs (1-3). DLBCL is also often associated with defective apoptosis or DNA 
repair. DLBCL is thought to arise from normal antigen-exposed B cells, however the 
 17 
exact cause and molecular mechanisms underlying these observations still remains 
unknown (1-3). It has been proposed that the initiating oncogenic event occurs early 
in B cell development but allows further differentiation to take place before 
subsequent oncogenic hits are sustained (Fig.1). The germinal center B cell is the 
normal counterpart of follicular lymphoma, Burkitt lymphoma, and most subtypes of 
diffuse large B cell lymphoma (DLBCL) (8-12) while the activated B cell-like (ABC) 
subtype of DLBCL resembles post–germinal center plasmablasts (6, 8, 9)(see also 
below).  Other follicular lymphoma and subtype of DLBCL may also originate from a 
bone marrow pre-B cell even though the malignant cells phenotypically resemble 
germinal center B cells. It has been also suggested that many of the genetic lesions 
that initiate lymphomagenesis are aberrant by-products of the enzymes that rearrange 
Ig segments to assemble the B cell receptor (BCR) in normal B cells (6). These 
distinct translocations that defines the subtypes of DLBCL and other lymphoma such 
as follicular lymphoma are caused by the RAG recombinase, which is active in pre-B 
cells but not mature B cells indicating that these B cell lymphoma cells participated in 
a germinal center reaction (6, 13).  
 18 
 
Fig.1 DLBCL cell development.  
(From Staudt, L. M. & Dave, S., The biology of human lymphoid malignancies 
revealed by gene expression profiling Adv Immunol. 2005, (14)). 
 
1.2 DLBCL subgroups and tumor classification 
DLBCL have been originally divided in at least 5 molecularly and clinically distinct 
subgroups: DLBCL not otherwise specified (DLBCL-NOS), which is the largest 
group of DLBCL, primary mediastinal B cell lymphoma (PM-DLBCL), T 
cell/histiocyte rich large B-cell lymphoma (T/HRBCL), primary gastric diffuse large 
B-cell lymphomas (PG-DLBCL) and unclassifiable DLBCL with features 
intermediate between DLBCL and Burkitt lymphoma (DLBCL/BL) (8, 15-20). 
Burkitt Lymphoma (BL) is a highly aggressive B-cell non-Hodgkin's non-DLBCL 
lymphoma that mainly affects children and young adults. BL is associated with 
Epstein–Barr virus (EBV) in 80-95% of cases (11, 21). Interestingly, T/HRBCL, an 
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uncommon rare morphologic variant of DLBCL is characterized by distinct clinico-
pathologic features, an active host immune/inflammatory response and increased 
expression of genes involved in T-cell receptor signaling, natural killer cell activation, 
complement cascade members and macrophage/dendritic cell markers. 
Based on gene expression profile analysis and origins, the mayor group, DLBCL-
NOS was recently reclassified into four biologically and clinically distinct subtypes: 
“germinal centre B-cell-like” (GCB)-DLBCL, “activated B-cell-like” (ABC)-DLBCL, 
primary mediastinal large B-cell lymphomas (PM-DLBCL) and a fourth group of 
DLBCL, which is represented by cases that remain non-classified, referred to as 
(NC)-DLBCL (2, 14-16, 19, 20). PM-DLBCLs are arising in the mediastinum of 
young adults, GCB-DLBCLs seem to derive from normal germinal center B cells (GC 
centroblasts), whereas ABC-DLBCLs may arise from post-germinal center B cells 
that are arrested during plasmacytic differentiation, though their cell of origin is not 
yet fully elucidated (2, 14-16, 19, 20). GCB-DLBCLs have ongoing somatic 
hypermutation of their immunoglobulin genes, a characteristic feature of normal 
germinal center B cells (22). The GCB-DLBCLs express genes characteristic of 
normal germinal-center B cells and are often associated with a good outcome. The 
GCB-DLBCL subtype is also characterized by low level of NF-!B activation and its 
survival is not dependent on NF-!B (23). On the other hand, key feature of the most 
aggressive DLBCL subtype, ABC-DLBCL, is the constitutive activation of nuclear 
factor kappa B (NF-!B)-dependent gene expression and its dependency on NF-!B 
activity for proliferation and survival (23). Moreover, ABC-DLBCL express genes 
characteristic of activated blood B cells and most of them are associated with a poor 
outcome (15, 20). 
More recent genome-wide gene expression studies revealed the existence of three 
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additional discrete DLBCL subsets. Based on their unique transcriptional profiles and 
associated clinical and genetic features, GCB-, ABC- and NC-DLBCL were further 
subdivided in oxidative phosphorylation (OXP)-DLBCL, B-cell receptor/proliferation 
(BCR)-DLBCL, and tumor microenvironment/host inflammatory response (HR)-
DLBCL (16, 19). The molecular profiles and clinico-pathologic features of HR-
DLBCL tumors resemble those of T/HRBCL (16). Primary HR-DLBCL tumors are 
associated with increased expression of subsets of inflammatory mediators including 
up-regulation of interferon (IFN)-! and NF-!B pathways (16, 24). The majority of 
HR-DLBCL belongs to the non-classified NC-DLBCL group, while smaller subsets 
belong to the ABC- and GCB-DLBCL (16, 19, 24, 25). Interestingly, the clinical 
outcome of the HR-DLBCL cluster is not improved, despite the increased 
inflammatory response (16, 19). Thus, it has been suggested that either their immune 
responses are inhibited by counter-regulatory mechanisms (i.e. through immuno-
editing) or HR-DLBCL tumors were resistant towards chemotherapy, or a 
combination of both (16, 24). HR-DLBCLs are often associated with chemo-
resistance (16, 19). Remarkably, HR-DLBCLs lack most of the common cytogenetic 
abnormalities (16, 19, 24, 25) and thus the exact molecular mechanisms underlying 
the oncogenic transformation and chemo-resistance in these tumors remain to be 
elucidated. 
 
1.3. Oncogenic pathways in DLBCL subgroups 
Transformation of normal B cell signaling pathways into malignant signaling 
pathways to sustain the growth and survival of DLBCL is accomplished through 
either gain-of-function mutations that activate signaling effectors or loss-of-function 
mutations that inactivate negative regulators of signaling or autocrine receptor 
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activation (26). One of the most compelling arguments supporting the view that the 
DLBCL subgroups represent distinct diseases is that they utilize distinct oncogenic 
mechanisms (Table 1). Insight into the molecular mechanisms underlying of the 
clinically distinct features of DLBCL subgroups has been provided by an analysis of 
regulatory factors that control the differentiation of germinal center B cells to plasma 
cells. As mentioned above the observed genetic abnormalities (i.e. translocation) often 
result in over-expression and constitutive activation of STAT3, STAT6, BCL2, 
BCL6, Rel factors and/or c-Myc, in DLBCLs (1-3).  
For instance, BCL6 is a transcriptional repressor that is required for mature B cells to 
differentiate into germinal center B cells during an immune response (27). Normal 
germinal center B cells express BCL6 at high levels but BCL6 expression is silenced 
during plasmacytic differentiation (28);(29);(30). In contrast the proto-oncogene gene 
product BCL6 is over-expressed in the majority of patients with aggressive DLBCL 
(31). Most DLBCLs belonging to the GCB subgroup constitutively express BCL6 at 
very high levels (8, 9, 20). Constitutive expression of BCL6 mediates 
lymphomagenesis through aberrant proliferation and cell survival (31). BCL6 can 
suppress both the basal and the inducible transcription of the tumor suppressors p53, 
p21 and or BLIMP1 in DLBCL (31-34). BCL6 gene is deregulated by chromosomal 
translocations in roughly 20% of DLBCLs (35) but the high constitutive expression of 
BCL6 in GCB-DLBCLs is not accounted for by these translocations. Rather, BCL6 is 
constitutively expressed in GCB-DLBCLs along with other germinal center B cell 
restricted-genes because these DLBCLs are derived from normal germinal center B 
cells and retain much of their biology (26).  
Another oncogenic translocation event occurs at the BCL2 locus. The t(14;18) 
translocation deregulates the BCL2 gene by placing it near the enhancer elements of 
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the immunoglobulin heavy chain locus. This oncogenic event was found to be 
common in GCB-DLBCL, occurring in about 45% of cases analyzed, and was also 
detected in about 20% of PM-DLBCL cases (2, 20, 36). In contrast, no BCL2 
translocations had been found so far in ABC-DLBCLs (2, 20). Nonetheless, the 
majority of ABC-DLBCLs express BCL2 mRNA at high levels, presumably due to 
transcriptional deregulation of the BCL2 gene (2, 9, 20). 
 
Table1. Distinct oncogenic mechanisms in the DLBCL subgroups  
(from Staudt, L. M. & Dave, S.,, The biology of human lymphoid malignancies 
revealed by gene expression profiling Adv Immunol. 2005, (14)). 
 
Many oncogenic events in B-cell lymphomas converge on the anti-apoptotic NF-!B 
pathways, often associated with over-activated survival signaling provided by the 
phosphatidylinositol-3 kinase (PI3K) and JAK kinase pathways (26, 37). Indeed, 
ABC-DLBCLs were found to have high expression of known NF-!B target genes 
when compared with GCB-DLBCLs (37). Remarkably the observed high constitutive 
activity NF-!B pathways in most ABC-DLBCLs are not connected to any 
amplification or translocations of the Rel-loci (26, 37). One of the most important 
differences among the DLBCL subgroups is the constitutive activity of the NF-!B 
pathway in ABC-DLBCL and PM-DLBCL but not GCB-DLBCL (26, 37). In this 
respect, PM-DLBCLs resemble Hodgkin lymphoma, which is also characterized by 
constitutive NF-!B activity (38-42). On the other hand, the amplification of the c-rel 
Figure 1.
A. Genes characteristically expressed by three subgroups diffuse large B-cell lymphoma
(DLBCL): Primary mediastinal B-cell lymphoma (PMBL), germinal center B-cell-like (GCB)
DLBCL, and the activated B cell-like (ABC) DLBCL (Rosenwald et al.,2002;Rosenwald et
al., 2003a;Wright et al., 2003). Each of the 201 columns represents gene expression data from
a single DLBCL biopsy sample and each row represents expression of a single gene. Relative
gene expression is indicated according to the color scale shown. B. Kaplan-Meier plot of overall
survival for the different DLBCL subgroups. C. Distinct oncogenic mechanisms in the DLBCL
subgroups. D. Selective toxicity of a small molecule I?B kinase inhibitor for ABC DLBCL
and PMBL cell lines (Lam et al., 2004).
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locus on chromosome arm 2p occurs in 16% of GCB-DLBCLs and in 25% of PM-
DLBCLs, but has never been detected in ABC-DLBCLs (2, 20, 43). C-Rel is a 
member of the anti-apoptotic NF-!B family of transcription factors. Nonetheless, this 
translocation does not result in constitutive expression of NF-!B factors in the 
majority of GCB-DLBCLs (26, 37).  
Together, the uneven distribution of these chromosomal abnormalities among the 
DLBCL subgroups suggests that the subgroups utilize distinct oncogenic pathways. 
More over, DLBCL simultaneously often activate several interconnected signaling 
pathways, resulting in distinct clinical outcomes, but at the same time also providing 
therapeutic opportunities and challenges. 
 
1.4. Clinical outcome and DLBCL lymphoma/ cancer therapies  
While tremendous progress has been made in understanding the molecular 
mechanisms underlying the biological heterogeneity in highly malignant aggressive 
DLBCL, much remains unknown about the molecular (patho-physiological) 
mechanisms, which determine the clinical outcome. It is therefore important to get 
more insight into the molecular mechanisms underlying their patho-physiology and to 
identify new targets for novel therapeutic treatments. Currently, chemotherapy 
(CHOP; cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone), 
combined with radiation and/or the anti-CD20 antibody Rituximab is the mainstays of 
lymphoma treatment. Optimal cancer therapies target the abnormal state of the cancer 
cell while sparing normal cells. Ideally, one hopes to identify and exploit “synthetic 
lethality” with therapies that target the oncogenic rewiring of malignant cells (44, 45).  
Although more than half of DLBCL patients can survive with current (immuno)-
chemotherapeutic regimes, the rest of them succumb to the disease. Thus, for the 
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remainder of these patients novel therapeutic strategies are required. Why some 
patients with DLBCL can be cured and others not has been a longstanding and is still 
being a frustrating open question. The recent gene expression profiling studies in 
clinically distinct classes of high risk DLBCLs revealed that signaling pathways 
might serve as novel (immuno)-chemotherapeutical targets in DLBCL, (2, 15, 19, 20). 
The constitutive activation of signaling pathways in lymphoma offers opportunities to 
intervene with tolerable effects on normal immune function. Moreover, B cell–
restricted transcription factors that are essential for lymphoma survival may also be 
amenable to attack because a short-term loss of normal B cells can be managed 
without risk to the patient. Indeed recent findings suggest that NF-!B pathways are 
potential therapeutic targets specific for ABC-DLBCL and PM-DLBCL, but not 
GCB-DLBCL. In support of this idea, small molecule inhibitors of inhibitor of !B 
(I!B) kinase were found to be selectively toxic for ABC-DLBCL and PM-DLBCL 
cell lines, but had no effect on GCB-DLBCL cell lines (46). In addition, the activated 
signal transducer and activator of transcription (STAT)-3 dependent signaling 
pathway can also serve as novel drug target in DLBCL (46-49).  In contrast to normal 
cells, in which STAT phosphorylation occurs transiently, it has been determined that 
STAT3 is persistently phosphorylated in most ABC-DLBCL in a autocrine and 
paracrine manner (from the tumor microenvironment) (47). Indeed, small molecule 
inhibitors of STAT3 signaling (nuclear translocation) were found to be selectively 
toxic for ABC-DLBCL (46, 48, 49). Recent studies provided also evidence that small 
molecule inhibitors targeting BCL6 can be selectively toxic towards high risk GCB-
DLBCL constitutively expressing BCL6 (50-53). Moreover, several genes, including 
the B-aggressive lymphoma protein 1 (BAL1) and BAL1-binding protein (BBAP) and 
Deltex E3 ubiquiton ligase 3 like (DTX3L) have been recently identified in a genome-
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wide screen for risk-related genes in high risk DLBCL (54, 55). For instance, BAL1 
and DTX3L are highly expressed in chemo-resistant HR-DLBCL with an active IFN! 
mediated host inflammatory response but not in cured low-risk tumors (25, 54, 55).  
 
1.5. Prostate cancer 
Prostate cancer is one of the leading causes of cancer-related mortality and morbidity 
in the aging male population and representing the most frequently diagnosed 
malignancy in men around the world (56, 57). Prostate cancer is a common clinically 
and molecularly heterogeneous disease and it is characterized by its aggressive 
metastasis. Similar to leukemias and lymphomas at least 50% of prostate cancers 
harbor recurrent gene rearrangements reflecting the distinct biology to prostate cancer 
subtypes including the aggressiveness of disease (56, 58-60). A common feature of 
many prostate cancer subtypes is the dependence on NF-!B and the activated signal 
transducer and activators of transcription (STAT)-3 and STAT6 for survival (57). 
Prostate cancer displays different stages and grades related to the aggressive 
metastasis disease (56, 57). Current therapeutic approaches for prostate cancer include 
active surveillance, surgery, radiation therapy, hormone therapy, chemotherapy and 
immunotherapy (57). The observed clinical and molecular heterogeneity associated 
with this common disease is still a mayor challenge in understanding prostate cancer 
(57-60). Most cases of clinically localized prostate cancer are curable with effective 
surgical and radiation treatments i.e. when the cancer is contained within the prostate 
(56, 57). Though, a significant percentage of patients with localized prostate cancer 
have radiation-resistant disease. Approximately 80% of all prostate cancer cases 
diagnosed are in early stages at which the therapeutic options are mostly curative. 
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However, the mortality rate of the remaining 20% of cases, diagnosed as metastatic 
tumors, is very high (56, 57).  
Patients diagnosed with prostate cancers and de novo metastatic tumors are generally 
treated with androgen deprivation therapy since the growth of prostate cancer is 
originally androgen dependent (56, 57). However, androgen deprivation therapy is 
primarily palliative, nearly all patients will eventually develop the androgen-
independent and highly metastatic form of prostate cancers (56, 57). Unfortunately, 
chemo-resistance remains the major obstacle in the treatment of androgen-
independent prostate cancer (57-60). Thus, novel therapeutic approaches to impede or 
prevent the progression of the disease remains to be developed for androgen-
independent prostate cancer, especially for treating chemo-resistant prostate cancers. 
 
1.6 IFN/JAK-STAT1/2 signaling pathways 
Interferons (IFN) encompass a family of secreted and pleiotropic cytokines that 
exhibit distinct antiviral, antiproliferative, immunomodulatory and antitumor 
properties (61-63). They are grouped into three classes called type I, II and III IFNs 
(61-63): Type I interferons consist of INF", INF#, IFN$, IFN%, IFN&, IFN! and 
IFN'. INF", INF# and IFN$, and are produced by nearly all cells, which get infected 
by viruses (61-64). IFN" is mainly produced by certain leukocytes (such as 
plasmacytoid dendritic cells and macrophages), while IFN# mainly produced by 
epithelial cells and fibroblasts (61-65). Knockout mice studies demonstrated that the 
type I interferons IFN", IFN# and IFN$ are primarily antiviral and have just little 
immunomodulatory activity but are essential for protective immunity to experimental 
infection by numerous viruses (61-65). The other type I interferons IFN%, IFN&, IFN! 
and IFN' play less well-defined roles, such as regulators of maternal recognition in 
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pregnancy (61-65). Type I interferon system plays a key role in shaping the antiviral 
adaptive immune response. Type II Interferon consists of one single interferon, 
namely INF!, which is produced only by the specialized and mitogenically activated 
T-cells and natural killer (NK)-cells. Its antiviral effects are less distinct than the one 
of type I, because its main effect is immuno-modulation. On the other hand type II 
interferon is critical for protective immunity to a number of intracellular bacteria, 
fungi, and parasites (61-65). Type III Interferon is also called INF( and produced by 
many cells. Its antiviral and immunomodulatory effect is weaker than the ones of type 
I or II (61-65).  
The IFN systems are well-controlled networks that require the coordinated regulation 
of immediate signaling events, rapid transcriptional activation and post-transcriptional 
control. The biological effects of IFNs are primarily mediated through the activation 
of the signal transduction pathway of the Janus kinases (JAK1-4) and signal 
transducers and activators of transcription (STAT) proteins, which in turn results in 
subsequent induction of IFN dependent genes (66-68). STAT proteins comprise a 
family of transcription factors (STAT1", STAT1#, STAT2, STAT3", STAT3#, 
STAT3!, STAT4", STAT4#, STAT5", STAT5#, and STAT6", STAT6#, STAT6!, 
Fig.2) that are essential for mediating cytokine- and growth factor-dependent cellular 
differentiation, proliferation, cell survival and apoptosis and immune function (68-
72). Genetic evidence indicates that the three STAT proteins STAT1 and STAT2 play 
a mayor role in immune function. STAT1-deficient mice exhibit a selective signaling 
defect in response to interferons (69-71)). Stat1(-/-) mice exhibit selective signaling 
defects in their response to both type-1 and type-II IFNs (70, 73, 74). Several reports 
demonstrated that Stat1(-/-) and Stat2(-/-) mice are highly sensitive to infection by 
microbial pathogens and viruses (69-71, 73-77).  
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Fig.2 Domain architecture of the STAT family and their isoforms.  
N: N-terminal dimerization/tetramerization domain, CC: coiled-coil domain involved 
in interaction with other proteins, DNA = DNA binding domain, SH2: SH2 domain, 
Y: phosphotyrosyl tail segment, TA: transactivation domain.  The Y and S residues 
involved in phosphorylation of the proteins are listed. (From Lim, C. P. & Cao, X. 
Structure, function, and regulation of STAT proteins, Mol Biosyst 2006 (72)). 
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Of the known JAKs and STATs, the JAK1, JAK2, and TYK2 kinases and the STAT1 
and STAT2 transcription factors play central roles in mediating IFN-dependent 
biological responses, including induction of the antiviral state (67, 70, 78, 79). IFN 
signaling is initiated through (IFNx) ligand interaction with specific trans-membrane 
receptor subunits of their corresponding receptors (Fig.3). Type I interferons (IFN", 
IFN#, IFN$, IFN! and IFN&) bind to a common type-I IFN receptor universally 
expressed on the cell surface, whereas IFN! uses a distinct receptor-complex (Type-II 
IFN receptor) for signaling that is not present on all cell types (67, 68, 78, 79). The 
subsequent receptor oligomerization leads to activation of either an intrinsic kinase 
domain or receptor associated JAK kinases, JAK1 and TYK2 kinases function in 
IFN"/# signaling, and the JAK1 and JAK2 kinases function in IFN! signaling. TYK2 
interacts with the IFNAR-1 receptor subunit, and JAK1 interacts with the IFNAR2 
subunit of the IFN"/# receptor. JAK1 also interacts with the IFNGR1 receptor 
subunit, and JAK2 interacts with the IFNGR2 subunit of the IFN! receptor (67, 78, 
79). The subsequent JAK-mediated tyrosine phosphorylation of latent cytoplasmic 
STAT proteins, resulting in STAT dimerisation via their Src homology (SH2) 
domain, translocation to the nucleus, complex formation with other transcription 
factors and binding to specific sequences to regulate gene transcription (66-68, 78, 
79). Each type of IFN activates different combinations of STAT proteins (78).  IFN$ 
triggers the phosphorylation of STAT1 but not STAT2. Activated STAT1 forms 
homodimers and migrates to the nucleus, where it binds to GAS sequences present in 
many promoters of primary IFN response genes (68, 78, 79). On the other hand upon 
IFN"/ß stimulation, both STAT1 and STAT2 are phosphorylated and activated and 
consequently heterodimerize and translocate to the nucleus, where they associate with 
IFN regulatory factor 9 (IRF9/p48) to form a STAT1:STAT2:IRF9 trimeric 
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transcriptional complex (ISGF3) (68, 78, 79). This trimer then binds to cis-acting 
IFN-stimulated response elements (ISREs) to induce transcription of primary IFN 
response genes (ISGs). The IFN response comprises a multi-array of IFN-stimulated 
gene products. Oligonucleotide microarray studies have shown that up to 700 genes 
are induced following treatment with IFNs depending on the cell type and conditions 
(63, 80). One of primary IFN response genes is the transcription factor and interferon 
regulatory factor (IRF)-1, which in turn enhances transcription of several secondary 
response genes. IRF1 acts aside with two other members of the interferon regulatory 
factor (IRF) family - IRF3 and IRF7 - as a major modulator of IFN-dependent gene 
expression (81).  
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Fig.3 IFN signaling pathways  
(Taniguchi T et al., IRF family of transcription factors as regulators of host defense, 
Annu Rev Immunol. 2001, (81)). 
 
 
1.7. Functional roles of the IL-4/STAT6 pathway 
The IFN$/STAT1-signaling pathway can also be antagonistically regulated by other 
STATs, mainly by STAT6 (69-71). Studies on knockout mice have demonstrated that 
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STAT6 is specifically activated in response to IL-4 and IL-13, another cytokine that 
binds to the chain of the IL-4 receptor (82). STAT6 is tightly connected to IL-4 and 
IL-13 signaling, and plays a key role in Th2 polarization of the immune system (69-
71). STAT6 plays an essential role in IL-4 signaling. Several reports showed that 
Stat6(-/-) mice have defects in IL-4- and IL-13-mediated functions including 
induction of CD23 and MHC class II expression, immunoglobulin class switching to 
IgE, B- and T-cell proliferation, decreased nitric oxide production of activated 
macrophages, Th2 cell development and thus have a reduced Th2-mediated immune 
response (69-71). On the other hand, they have elevated levels of IL-2 and showed an 
increased Th1-mediated immune response (69-71). Th2 cells produced IL-4 is an 
important negative regulator of proinflammatory gene expression. For instance, IL-4 
is able to suppress transcriptional activation of IFN!/STAT1-responsive pro-
inflammatory genes through the ability of STAT6 to sequester coactivator molecules 
that may be required for the transcriptional action of STAT1 (82-86). On the other 
hand, IFN"/# and IFN! have been shown to suppress IL-4/IL-13-inducible gene 
expression by inhibiting tyrosine phosphorylation and nuclear translocation of 
STAT6, for example in monocytes and fibroblast cells (82-86). Recent reports 
demonstrated that IFN"/ß can also activate complexes containing STAT6, 
predominantly in B cells and hepatocytes (87). Activation of STAT6 by IFN"/ß in B 
cells is accompanied by the formation of novel STAT2:STAT6 complexes (87). Thus, 
the intracellular mechanisms that mediate these antagonistic responses appear to be 
multifactorial. 
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1.8 Regulation of IFN/STAT1/2 signaling pathways 
The interferon system is a well-controlled network that requires the coordinated 
regulation of immediate signaling events, rapid transcriptional activation, and post-
transcriptional control. Stringent control of the IFN system allows swift elimination of 
tumor cells and pathogens and beneficial immunomodulatory functions prior to the 
onset of deleterious consequence for the host. Such controls offer a fine-tuning 
mechanism for efficient and rapid response and as a negative feedback control in IFN 
biosynthesis and response. The post-transcriptional mechanisms occur at multiple 
levels, including mRNA stability, alternative splicing, translation, and post-
translational modifications (63). The threshold, magnitude and specific responses 
elicited by IFN stimulation are tightly controlled and mainly negatively regulated by 
numerous inducible negative feedback mechanisms including tyrosine phosphatases, 
receptor internalization, proteasomal degradation of signaling adaptor molecules, 
soluble receptor antagonists and specific inhibitors, including the suppressor of 
cytokine signaling (SOCS) proteins (reviewed in (88)). SOCS proteins have been 
revealed as key negative regulators of cytokine and growth factor signaling that can 
interfere with signaling not only from the inducing cytokine in a classic “negative-
feedback” loop, but also to regulate signaling downstream of other cytokines. SOCS 
proteins inhibit components of the cytokine-signaling cascade via direct binding or by 
preventing access to the signaling complex. SOCS1 has been shown be the key SOCS 
protein playing an essential regulatory role in innate immunity (88). SOCS1 can 
interact with phosphotyrosine residues on the IFNAR1 and IFNGR1 subunits in a 
JAK1-independent manner, thus abrogating tyrosine phosphorylation of transcription 
factor STAT1 and reducing the duration of IFN dependent gene expression. In 
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addition, SOCS can block signaling by direct inhibition of JAK enzymatic activity 
(reviewed in (88)).  
 
1.9 IFN/STAT1 signaling pathway in tumorigenesis 
Genetic studies demonstrated that the type I interferons IFN" and IFN# as well as the 
single type II interferon IFN! play a mayor role as central coordinators of tumor-
immune-system interactions (61, 63, 89). IFN$ plays a pivotal antitumor role since 
IFN$ or IFN$ receptor knockout mice show increased tumor development. 
IFN$ promotes direct tumor suppressive effects by inhibiting cellular proliferation, 
promoting apoptosis and inhibiting angiogenesis (90, 91). Paradoxically, IFNs have 
been shown to exhibit both pro- and antitumor properties (63, 89, 92). IFNs are 
suggested to modulate the host response to tumors in two different ways. Initially, 
IFNs aid protecting the host from tumor formation and development (immuno-
surveillance), but subsequently IFNs could also promote the tumors to resist attack 
(63, 89, 92). The pressure to recognize and eliminate all precancerous or cancerous 
cells by cells of the innate and adaptive immunity enhances the outgrowth of new 
mutated tumor variants with reduced immunogenicity that can escape the immune 
system and favor progression to detectable malignancies (immuno-editing) (92). Type 
I and Type II IFNs play a central role in the process of cancer immuno-editing (93, 
94). The constant presence of type I and/or type II IFNs in the microenvironment, can 
result in a selection of tumor cells, which are no longer sensitive to interferons (20).  
Moreover, subsets of these tumor cells, can intrinsically produce constitutively 
interferons, and have also upregulated STAT1 and/or STAT2 (20). The tumor 
suppressor STAT1 is considered a key regulator of the surveillance of developing 
tumors. Deregulation of STAT signaling pathways is often associated with solid 
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tumors and leukemia (68, 78). STAT1 and STAT4 are mainly acting as tumor 
suppressor genes and their inactivation contributes to malignant transformation while 
the other STATs STAT3, STAT5 and STAT6 have been suggested to have mainly 
oncogenic functions and promoting survival of tumor cells (reviewed in (95-97)). For 
instance, Stat6(-/-) mice have enhanced immunosurveillance against primary and 
metastatic tumors since Stat6(-/-) mice are unable to generate a (IL-4 mediated) type 2 
immune response, and instead mount an enhanced (IFN mediated) type 1 response 
(98, 99). Moreover, constitutively activated STAT6 has been found in patient samples 
isolated from prostrate cancer tissues, Hodgkin lymphomas, primary mediastinal large 
B cell lymphomas and T cell leukemia/lymphomas (100, 101). Both STAT6 and 
STAT1 have been suggested to act as crucial antagonistic regulators in the 
pathogenesis of solid tumors and leukemias (68, 78). 
Remarkably, recent studies revealed that STAT1 acts both as a tumor suppressor and 
oncogene depending on the context and cancer type (102, 103). For instance loss of 
STAT1 in mice predisposes to intraepithelial neoplasias (104). On the other hand 
Stat1(-/-) mice are partially protected from leukemia development, indicating that 
STAT1 acts as a tumor promoter for leukemia development (105). The role of STAT2 
in tumorigenesis is not yet clear but recent Stat2(-/-) mice model studies identified 
STAT2 as a novel contributor to colorectal and skin carcinogenesis that may act to 
increase the gene expression and secretion of proinflammatory mediators, which in 
turn activate the oncogenic STAT3 signaling pathway (106). 
The tumor suppressive effects of IFN$ are mainly mediated through one of the mayor 
target of STAT1, the interferon regulatory factor-1 (IRF1). IRF1 and its functional 
antagonist IRF2 are not only mayor regulatory factor in innate immunity involved in 
the regulation of normal haematopoiesis and leukaemogenesis (107, 108). Beside its 
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crucial role in innate immunity IRF1 can also act as tumor suppressor and mediates 
anti-proliferative and pro-apoptotic effects in cancer cells in a context dependent and 
cell type- specific manner (81, 109-112). IRF1 is critical for IFN$-mediated immune 
surveillance (113, 114). Many tumors lacking IRF1 or have reduced IRF1 expression 
levels (111, 112). Although loss of IRF1 alone seems not to be associated with 
spontaneous tumor development in mice, it greatly increases tumor susceptibility in 
combination with loss of other tumor suppressor proteins such as p53 (111). In 
absence of antagonistic regulatory factors, such as the oncogene IRF2 increased 
expression and activation of IRF1 inhibits the expression of pro-survival members of 
the BCL2 family and simultaneously induces the expression and activation of anti-
proliferative and pro-apoptotic genes, including cyclin-dependent kinase (CDK) 
inhibitor p21WAF1 or CASP3 (107, 115, 116). IRF1 induces both ligand-dependent 
(extrinsic) and ligand-independent (intrinsic) caspase-mediated apoptosis (110). 
Finally a recent study suggests that IRF1 is also an essential mediator of the crosstalk 
between tumor cells and NK cells that mediate immune surveillance in the metastatic 
niche (113, 114). 
 
1.10 Chemo- and radioresistance in cancer and the IFN/STAT1 signaling 
pathway 
Several recent studies strongly indicate that transcription factor STAT1 is involved in 
chemo and/or radiation resistance of solid tumors (117-122). For instance, 29% of 
clinical human prostate cancers analyzed, constitutively expressed STAT1 and 
interferon stimulated genes (ISGs) in vivo (118). STAT1 has been therefore suggested 
as a potential target for radiosensitation of aggressive tumors that constitutively over-
express IFN$/STAT1-dependent pathways. It has been shown that multiple small 
 37 
doses of RI can activate an IFN(", # and $)-related, STAT1-dependent DNA damage 
gene expression signature (including STAT1, G1P2, G1P3, IFITM1, IFIT1, IRF9, 
MX1, HLA-C, OAS1 and OAS3) in prostate cancer (117-121). Moreover, in vitro 
selection against IFN" or IFN$ and constitutive expression of STAT1 leads to an IFN- 
and radioresistant phenotype in prostate tumor cells (117, 118). In addition, the 
IFN/STAT1 signaling pathway is also up-regulated in chemo-resistant prostate cancer 
cells (118, 119). Remarkably, STAT1-dependent chemo-resistance was also 
associated with increased resistance to ionizing radiation and accompanied by the up-
regulation of ISGs that overlapped, in part, with the IFN/DNA damage gene 
expression signature (117, 118). However, the exact molecular mechanisms how 
STAT1 signaling pathways mediate chemo- and radio-resistance in prostate cancer 
(Fig. 4 shows the current model) and potentially in other cancer types remains to be 
elucidated. 
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Fig.4 Radio and chemoresistance and the IFN/STAT1 pathway  
(from N.N. Khodarev et al., Clin Molecular pathways: interferon/stat1 pathway: role 
in the tumor resistance to genotoxic stress and aggressive growth, Cancer Res, 2012, 
(118)). 
 
 
1.11 STAT6 signaling pathways and chemo- and radioresistance in cancer  
Aside the dual role of IFNs in tumorigenesis, recent studies demonstrated that 
aberrant activation of IL-4 receptor signaling and constitutively activated IL-4/STAT6 
target genes is frequently associated with the pathophysiology of leukemia and 
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lymphoma cells (89). However, less is known about the tumorigenic roles of the 
STAT6, especially regarding chemo- and radioresistance. STAT6 is highly expressed 
in subtypes of prostate cancer, DLBCL and chronic lymphocytic leukemia (CLL) and 
its expression significantly correlated with tumor size in vivo (101, 123, 124). The IL-
4/STAT6 signaling pathway has been suggested to be required for survival and 
induces proliferation and migration in prostate cancer under stress (101). 
Interestingly, recent studies showed that IL-4/STAT6 signaling pathway induced 
broad resistance to the cytotoxic drugs in chronic lymphocytic leukemia (CLL)(124), 
thus providing preliminary evidence that IL-4/STAT6 signaling is also involved in 
chemo-resistance of tumor cells. 
 
 
CHAPTER2.  
2.1 ADP-ribosylation reaction: 
One of the most dynamic ways to regulate signaling and transcriptional processes is 
through post-translational modifications (PTMs) of proteins, such as phosphorylation, 
acetylation, methylation, ubiquitination or (n)ADP-ribosylation. PTMs are 
fundamental to the regulation of the physiology, the behavior, and the fate of cell. 
Among these modifications, ADP-ribosylation is both an established and a rapidly 
emerging PTM involved in a variety of essential cellular processes (125-127). Mono- 
and polymerizing-ADP-ribosylation of proteins are phylogenetically ancient, 
reversible, covalent post-translational modifications implicated in a wide range of 
processes (Fig. 5) (126). Mono-ADP-ribosylation of proteins was originally identified 
as the pathogenic mechanism of certain bacterial toxins, which function as virulence 
factors (126, 128, 129). Intracellular (n)ADP-ribosylation has been suggested to play 
 40 
important roles in the regulation of intracellular signaling cascades, gene expression, 
as well as cell differentiation and proliferation (125, 126, 128, 130, 131). However, 
nothing is known about the regulation of IFN/STAT1 dependent signaling through 
mono or poly-ADP ribosylation. Interestingly, a recent report provided first evidence 
that IL-4-signaling and STAT6-mediated transcriptional responses might be indeed 
regulated through mono-ADP-ribosylation of transcriptional coactivators of STAT6 
such as p100 (132). 
 
 
 
FIG.5 The ADP-ribosylation reaction cycle  
(From Hottiger et al., Progress in the function and regulation of ADP-ribosylation, 
Sci. Signaling, 2011 , (133)). 
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2.2 The Diphtheria toxin-related ADP-ribosyltransferase (ARTD) family 
The mono-ADP-ribosylation reactions are catalyzed by mono-ADP-
ribosyltransferases (ARTs), which transfer a single ADP-ribose moiety of NAD+ to a 
specific amino acid residue (i.e. on glutamate residues) of the acceptor protein (126). 
The related polymerizing-ADP-ribosylation reaction catalyzed by polymerizing-ADP-
ribosyltransferases (former poly-ADP-ribose-polymerases, PARPs) includes, in 
addition to the mono-ADP-ribose transfer reaction, an elongation step that results in 
the synthesis of poly-ADP-ribose chains processes (125) (126) (Fig. 5).  In eukaryotic 
cells, cellular protein-mono-ADP-ribosylation reactions that modify arginine, 
glutamate and potentially cysteine residues of acceptor proteins have been detected in 
vivo (reviewed in (126, 134). In eukaryotes, mono-ADP-ribosylation of arginine and 
cysteine residues seems to occur on both extracellular and intracellular target proteins 
while (n)ADP-ribosylation of glutamate residues seems to be restricted to the nucleus 
and cytoplasm (126). 
Currently, more than 30 human genes encoding proteins that possess either an ADP-
ribosyltransferase or ADPr-protein(glyco)hydrolase catalytic domain are known. The 
only family of intracellular ADP-ribosyltransferases characterized so far encompasses 
the Diphteria toxin-like mono- and polymerizing-ADP-ribosyltransferases (ARTDs, 
former PARPs) (125-127, 135). It has been recently demonstrated that several 
identified intracellular mammalian Diphtheria toxin-related ADP-ribosyltransferases 
(such as the ARTD7/BAL3, ARTD8/BAL2, ARTD10, ARTD12 and ARTD15) 
exclusively functions as mono-ADP-ribosyltransferases (127, 136). Thus, the 
mammalian Diphtheria toxin-related ADP-ribosyltransferases were recently grouped 
under a new, unified nomenclature, referred to as ARTDs (135). The mammalian 
ARTD family encompasses 18(17) members (Fig. 6). Based on recent structural and 
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enzymological analysis the ARTDs can be divided into four mayor groups: (1) mono-
ADP-ribosyltransferases, (2) polymerizing-ADP-ribosyltransferases, (3) inactive 
mono-ADP-ribosyltransferase enzymes, including BAL1/ARTD9, and (4) most likely 
also inactive polymerizing-ADP-ribosyltransferases such as ARTD3 or ARTD4 
(137). The mono-ADP-ribosylating members of the ARTD family are very likely 
representing a missing link and are responsible for most mono-ADP-ribosylation 
reactions in mammalian cells. The ARTD family can be further subdivided into 
different subclasses based on their activity and overall domain structures. One of 
these subclasses includes the active and inactive macro domain-containing mono-
ADP-ribosyltransferases and B-aggressive lymphoma proteins BAL1/ARTD9, 
BAL2/ARTD8 and BAL3/ARTD7, described as novel risk-related proteins in diffuse 
large B-cell lymphomas (127, 137). 
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Fig.6 Domain architecture of the human ARTD (PARP) family.  
The following BAL related functional domains are indicated: The ART domain is the 
catalytic core required for basal ART activity. The WWE domain is named after three 
conserved residues (W-W-E), and is predicted to mediate specific poly-ADP-ribose 
mediate protein-protein interactions in ubiquitin- and ADP-ribose conjugation 
systems. The Macro or A1pp domains are structurally related to the catalytic domain 
of enzymes that process ADP-ribose-1%-phosphate, a reaction product derived from 
ADP-ribose 1%-2% cyclic phosphate generated by ARTD18/TpT. The Macro domain 
can also serve as mono-ADPr or O-acetyl-ADP-ribose binding module. ZF: zinc 
finger domains. RRM is a poly-ADP-ribose and RNA-binding/recognition motif. 
Within each ART domain, the region that is homologous to the ARTD signature 
(residues 859–908 of ARTD1) as well as the equivalent of the ARTD1 catalytic E988 
is shaded. (From Hottiger MO. et al., Toward a unified nomenclature for mammalian 
ADP-ribosyltransferases, Trends Biochem Sci., 2010 (135) 
 
 
2.3 Mono-ADP-ribose-protein hydrolases  
The extent of post-translational modification by mono-ADP-ribosylation depends on 
mono-ADP-ribosyltransferases and mono-ADP-ribose-protein-hydrolases (mARHs) 
that antagonize each other ((138, 139) and reviewed in (126, 140)). Amino acid-
mono-ADP-ribose-specific mARHs cleave the ribose-amino acid bond, leading to 
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release of mono-ADP-ribose and regeneration of the free reactive group of the 
corresponding amino acid residue ((138, 139) and reviewed in (126, 140)). This 
indicates that mono-ADP-ribosylation of proteins is a reversible process and that this 
modification is most likely of regulatory importance (126, 138, 140-143). Thus 
mARTs and mARHs are opposing arms of ADP-ribosylation cycles. The relevance of 
reversible mono-ADP-ribosylation of cytoplasmic proteins has obtained support from 
a recent study demonstrating that mono-ADP-ribose-arginine hydrolase-1 (Marh1) 
knockout mice are more sensitive to cholera toxin, Cholera toxin produced by Vibrio 
cholerae causes the devastating diarrhea of cholera by mono-ADP-ribosylation of "-
subunits of intestinal heterotrimeric GTP-binding proteins, which results in severe 
water and electrolyte losses (144). Moreover, a recent study showed that Marh1(-/-) 
and Marh1(+/-) mice spontaneously develop lymphomas, adenocarcinomas, and 
metastases more frequently than wild-type mice (145). This study strongly indicates 
that tight control of protein mono-ADP-ribosylation levels mediated by ARH1 is 
essential for cancer suppression. However nothing is known about the ARTD specific 
mono-ADP-ribose-protein hydrolases that cleave the ribose-glutamic acid bond. 
Interestingly, recent studies showed that the human macro domain containing proteins 
MDO1, MDO2 and MDO3/c6orf130 could serve as bona fide O-acetyl-ADP-ribose 
(OAADP-ribose) hydrolases (146, 147), see also next section. Indeed, the proposed 
catalytic core structures of the macro domains of MDO1, MDO2 and MDO3/c6orf130 
unexpectedly strongly resembles those of nucleotide triphosphate hydrolases and non-
canonical poly-ADP-ribosyl-protein-glycohydrolases (148), strongly indicating that 
these macro domains may also function as an esterase towards E/D-ADP-ribose-ester 
bonds in ADP-ribosylated proteins, thus acting as ARTD specific mono-ADP-ribose-
peptide-hydrolases.  
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2.4 Macro domains are ADP-ribose-protein modules 
The macro domain is an evolutionary conserved protein module and is found 
associated with specific histone variants, such as macroH2A1.1, mono-ADP-
ribosyltransferases, including BAL1/ARTD9, transcriptional coactivators such as 
ALC1/CHD1L and MDO1/LRP16 as well as with largely uncharacterized proteins, 
such as MDO2 and MDO3/c6orf130 (149, 150). In addition, a small number of 
animal RNA viruses encode macro domains (reviewed in (151)). (150). A subset of 
macro domains including those of mono-ADP-ribosyltransferases can serve as 
binding modules for free mono-ADP-ribose, OAADP-ribose and mono-ADP-
ribosylated proteins (149, 150) and own unpublished observations). Remarkably, all 
BAL1-3/ARTD7-9 exist in different isoforms, containing either only one 
(BAL1/ARTD9 and BAL3/ARTD7) or 2 (BAL2/ARTD8) macro domains (own 
unpublished observations). Thus their proposed tumor promoting and immuno-
modulatory activities could be regulated through the NAD/ADPr metabolite-binding 
activity of their macro domains. There is preliminary evidence, that macro domains 
may modulate transcription, for example they are able to repress transcription by 
binding to a promoter (11).  
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2.5 Roles of the B aggressive lymphoma proteins and ADP-ribosyltransferases 
BAL1/ARTD9, BAL2/ARTD8 and BAL3/ARTD7 in innate immunity and 
tumorigenesis  
The macro domain-containing mono-ADP-ribosyltransferases and B-aggressive 
lymphoma proteins BAL1/ARTD9, BAL2/ARTD8 and BAL3/ARTD7 are nucleo-
cytoplasmic shuttling proteins (25, 54, 55, 132, 152). Both, BAL2/ARTD8 and 
BAL3/ARTD7 are active mono-ADP-ribosyltransferases while no auto-modification 
or trans-mono-ADP-ribosyltransferase activity could be observed so far for 
BAL1/ARTD9 ((25, 127) and own unpublished observations). Thus BAL1/ARTD9 is 
most likely an inactive ARTD. All three BAL/ARTDs contain 2 or 3 macro domains 
in their N-terminal part (Fig. 7, see also section macro domains). BAL1-3/ARTD7-9 
and BBAP/DTX3L are highly inducible proteins and only constitutively expressed in 
vivo at extremely low levels in lymphocyte-rich tissues (153). However, expression of 
BAL1-3/ARTD7-9 and BBAP/DTX3L is highly induced upon stimulation with IFN!, 
IFN"/#, or upon infection with H. pylori, S. typhimurium and various RNA viruses 
((153-157) and own unpublished observations).  
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Fig.7 MacroARTD molecular structures.  
(from Hans C. Winkler, Identification of p62 as interaction partner of ARTD9-is 
ARTD9 degraded by autophagy?Inaugural-Dissertation, 2012)  
 
 
BAL1/ARTD9 has been initially identified as a novel risk-related gene that is 
constitutively over-expressed in aggressive chemo-resistant subsets of host response 
(HR) subtypes of diffuse large B-cell lymphoma (DLBCL) tumors (25, 55). In mice, 
BAL1/ARTD9 is developmentally regulated and mainly expressed (although at very 
low levels) in the thymus, in specific regions of the central nervous system and of the 
gut with the highest expression in the thymus and intestine (153). In adult mice, the 
highest levels of BAL1/ARTD9 expression (though still very low) were found in the 
medulla of the thymus and the white pulp of the spleen, suggesting a role for 
BAL1/ARTD9 in thymocytes maturation (153). In addition high expression levels of 
BAL1/ARTD9 were also detected in specific regions of the brain (dentate gyrus 
regions of the hippocampus) and in the epithelium of the duodenum, jejunum, ileum, 
and colon (153). 
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BAL1/ARTD9 has been proposed to be associated with lymphocytes migration and 
may promote the dissemination of malignant B cells in high-risk DLBCL in vivo (25). 
BAL1/ARTD9 over-expression has been shown to lead to increased responsiveness to 
the chemokine stromal cell-derived factor 1alpha (CXCL12/SDF-1) (25), though the 
molecular mechanism underlying this observation is not yet known. Doxo-cyclin-
induced over.expression of BAL1/ARTD9 in BAL1/ARTD9 non-expressing low risk 
GCB-DLBCL led to the induction of a very small subset of interferon (IFN) related 
genes (25), thus providing preliminary evidence that BAL1/ARTD9 might play a 
direct role in IFN signaling pathways (25). However, the exact molecular functions 
and regulatory mechanisms of BAL1/ARTD9, especially in high-risk HR/ABC type 
DLBCLs, are not yet known and remains to be elucidated. For instance, it is not 
known whether any trans-mono-ADP-rbosylation activity is required for these 
functions. 
Several recent studies by the Boothby lab provided preliminary evidence that 
BAL2/ARTD8, also referred to as collaborator of STAT6 (CoaSt6) interacts with 
STAT6 in vivo and amplifies STAT6-mediated gene expression pathways activated 
by interleukin 4 (132, 152). BAL2/ARTD8 has been suggested to functions as 
STAT6-specific co-regulator of IL-4 mediated gene expression in T-cells (132, 152). 
BAL2/ARTD8 is more weakly expressed than BAL1/ARTD9 in the thymus (153), 
but may also play a role during thymic development and function, because this organ 
seems to be the major site of BAL2/ARTD8 expression during development and in 
adulthood (153). In addition, expression of BAL2/ARTD8 seems also to be 
particularly high in the intestinal epithelium that covers Peyer's patches and colon 
lymphoid follicles (153). Remarkably, BAL2/ARTD8 functions as a highly selective 
co-activator/co-regulator of STAT-mediated gene expression, since it does not appear 
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to increase IFN!-induced STAT1-dependent gene expression (132, 152). This study 
also provided preliminary evidence for a role of the BAL2/ARTD8-associated mono-
ADP-ribosylation activity in STAT6-mediated transcriptional response (132). A 
catalytically fully inactive mutant of BAL2/ARTD8 was unable to enhance STAT6-
mediated transcription of a test promoter (132). BAL2/ARTD8 has been suggested to 
mono-ADP-ribosylate p100, another co-activator of STAT6 (132). Interestingly, 
association of BAL2/ARTD8 with STAT6 was partially dependent on its macro 
domains (132, 152), indicating that STAT6 might be mono-ADP-rbosylated in vivo.  
Recent studies provided first evidence that BAL2/ARTD8 may play crucial roles in 
vivo. A recent study using a mice model of BAL2/ARTD8 provided first evidence 
that BAL2/ARTD8 might be involved in mediating IL-4-induced proliferation and 
protection of B-cells against apoptosis following irradiation or growth factor 
withdrawal (158). In addition it has been suggested that BAL2/ARTD8 could 
influence Myc-induced oncogenesis by increasing the cellular metabolic rates (158). 
BAL2/ARTD8 knockout mice showed a reduced susceptibility to B cell lymphoma in 
a c-Myc-driven Burkitt lymphoma like tumor model (158). An earlier in vitro study 
already suggested that BAL2/ARTD8 might be connected with glycolysis, through 
the ubiquitinylation dependent regulation of phosphoglucose isomerase/autocrine 
motility factor activities (159). More recently, a study provided preliminary evidence 
that BAL2/ARTD8 can also act as an IL-4/STAT6 independent effector of the JNK2-
dependent pro-survival signal in multiple myeloma (160). BAL2/ARTD8 is 
constitutively over-expressed in myeloma plasma and seems to be associated with 
disease progression and poor survival (160). BAL2/ARTD8 promotes the survival of 
myeloma cells by binding and inhibiting c-Jun N-terminal kinase (JNK)-1 kinase 
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activity (160). However, the exact molecular mechanisms and the functional role of 
its mono-ADP-rbosylation activity remain to be elucidated.   
The third member, BAL3/ARTD7 exists in three different isoforms, BAL3/ARTD7 
full-length, containing two macro domains and 2 short isoforms, containing only one 
macro domain ((54, 55) and own unpublished observations). BAL3/ARTD7 could 
therefore be regulated through the NAD metabolite-binding activity of its macro 
domains. BAL3/ARTD7 has been implicated in both regulates stress responses and 
microRNA activity in the cytoplasm as well as in macro domains mediated repression 
of transcription in the nucleus (54, 161, 162). BAL3/ARTD7 can act as transcriptional 
repressor when tethered to a promoter as a GAL4-DBD-fusion protein (54). 
Interestingly, this study provided evidence that the macro domain of BAL3/ARTD7 
alone can repress transcription (54). 
Collectively, the macro domain-containing mono-ADP-ribosyltransferases and B-
aggressive lymphoma proteins BAL1/ARTD9 and BAL2/ARTD8 could act both as 
tumor promoting factors and regulators of innate immunity by modulating expression 
of host or pathogen induced tumor and pathogen-specific factors. Moreover, since 
BAL1/ARTD9 and BAL2/ARTD8 are involved in the regulation of gene expression 
activated by IFN! and/or IL-4 respectively, they could antagonistically function in the 
immune response as well as in tumorigenesis (25, 132, 152). IFN! and IL-4 can 
antagonize each other's function in thymocyte maturation and macrophage activation 
during the immune response (83-86). 
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2.6 Proposed Roles of the BAL1/ARTD9 binding partner and E3 ubiquitin ligase 
BBAP/DTX3L 
BBAP/DTX3L was originally identified as a binding partner of BAL1/ARTD9 (163) 
and belongs to the E3 ligase family of Deltex (DTX) proteins (25). BBAP/DTX3L is 
also over-expressed in subtypes of high risk chemotherapy-resistant “host response” 
(HR) DLBCL (25, 163) and has been suggested to regulate the subcellular 
localization of BAL1/ARTD9 by a dynamic shuttling mechanism (25). 
BBAP/DTX3L has been suggested to facilitate nuclear export and shuttling of 
BAL1/ARTD9 from the nucleus to the cytoplasm (25). BBAP/DTX3L is essentially 
co-expressed with BAL1/ARTD9 during development and in adult tissues strongly 
indicating that BAL1/ARTD9 functions mainly in the cytoplasm in most cells. 
However, the exact molecular mechanism(s) remains to be elucidated. A recent study 
demonstrated that BBAP/DTX3L can selectively monoubiquitinate histone H4 lysine 
91 and protects cells exposed to DNA damaging agents (164). However whether 
BBAP/DTX3L could also selectively monoubiquitinate signaling factors of the IFN! 
or IFN"/# such as BAL1/ARTD9, STATs or IRF1 remain to be investigated. 
 
 
2.7 Cross-talk between BAL1/ARTD9 and other ARTDs through ADP-ribose 
metabolites and (n)ADP-ribose binding modules? 
Many ARTD family members contain domains, which could serve as mono and poly 
ADP ribose binding modules, such as RRM, WWE and macro domains (Fig. 8). 
Several recent studies provided biochemical and structural evidence that the macro 
domains of macro domain containing ARTDs can also serve as high-affinity binding 
modules for free ADP-ribose and mono-ADP-ribosylated proteins (165). Remarkably, 
 52 
recent studies provided strong evidence that the WWE domain recognizes specifically 
poly(ADP-ribose) (PAR) but not mono-ADP-ribose by interacting with iso-ADP-
ribose (166, 167). These studies further demonstrated that PAR binding is a common 
function for the WWE domain family including those of ARTDs (166, 167). Thus, the 
WWE domain containing ARTDs (such as BAL2/ARTD8) could specifically interact 
with poly-ADP-rbibosylated proteins including polymerizing ARTD members such as 
ARTD1. These studies strongly indicate that the macro domain containing ARTDs 
such as such as BAL1/ARTD9 or such as BAL2/ARTD8 may be not only regulated 
through OAADPR and free mono-ADPR but could also directly interact with each 
other or even with other mono-ADP-ribosylated and potentially also poly-ADP-
ribosylated ARTDs, including the polymerizing ARTD member ARTD1. 
 
Fig.8 BAL related ARTD-associated (n)ADP-ribose binding modules 
Macro-domain: mono-ADP-ribose binding domain, RRM: poly-ADP-ribose and RNA 
binding domain, WWE: poly-ADP-ribose binding domain. (modified from Kalisch T. 
et al, New readers and interpretations of poly(ADP-ribosyl)ation TIBS 2012 (168)). 
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2.8 ARTD/PARP inhibitors and concept of “synthetic/conditional lethality” 
effects towards tumors 
Recent preclinical and clinical studies provided preliminary evidence that 
ARTD/PARP inhibitors might be promising drugs in the treatment of human 
malignancies including lymphomas and prostate cancer. Potent ARTD/PARP 
inhibitors with a high specificity towards ARTD1 and ARTD2, such as Olaparib 
(Astra Seneca/KUDOS) and ABT-888 (veliparib, Abbott Laboratories) have been 
developed that are not only effective as tumor cell radio- and chemo-sensitizers but as 
well as single agents to selective kill tumors in vivo. Biologically active doses of 
PARP inhibitors caused minimal syngenic toxicity in animal models and in phase I to 
II clinical trials. Several ARTD/PARP inhibitors are currently being further studied at 
the clinical trial phase III, specifically olaparib, and veliparib 
(http:/www.clinicaltrials.gov/). ARTD/PARP inhibitors are believed to exert their 
antitumor effects through at least two distinct but potentially complementary effects: 
1) Through a "synthetic" lethal effect whereby continuous exposure of replicating 
cells to an ARTD/PARP inhibitor causes a significant increase in DNA DSB repair 
activity and defects in repair of DNA replication forks causing subsequent death in 
tumor cells deficient in HR. Two genes (‘A’ and ‘B’) are said to be ‘synthetic lethal’ 
if mutation of either gene alone is compatible with viability but simultaneous 
mutation of both genes causes death (45, 169-171). This concept can be extended to 
situations in which simultaneous mutation of two genes impairs cellular fitness more 
than mutation of either gene alone (45, 169-171).  The concept of synthetic lethality is 
now used to choose anticancer drug targets. For instance, the protein products of 
 54 
genes that are synthetic lethal to known cancer-causing mutations (such as ATM, 
BRCA1, BRCA2, and NBS1, if amenable to pharmacological attack (for example, if 
they encode an enzyme such as ARTD1), should theoretically represent excellent 
targets for anticancer therapy. Indeed, ARTD/PARP inhibitors seem to be highly 
effective as a single agent in patients whose tumors have germline or somatic defects 
in DNA damage repair genes (i.e. ATM, BRCA1, BRCA2, and NBS1) or defects in 
genes involved in phosphatase and tensin homolog gene (PTEN) signaling, 
confirming that inhibition of ARTDs (mainly ARTD1 and ARTD2) exerts "synthetic 
lethality" effect towards tumors [15]. ARTD1/PARP1 and its close relative 
ARTD2/PARP2 are known to play a role in the cellular response to DNA damage, 
and an important role for ARTD/PARP inhibitors as sensitizers to cytotoxic DNA 
damaging agents has emerged [12-14].  
2) ARTD/PARP inhibitors also exert their antitumor effects through "conditional" 
lethality effect whereby ARTD/PARP inhibition may cause sensitization to 
therapeutic DNA damage in tumor cells. This "conditional" lethality approach 
exploits a postulated differential reliance on the DNA repair pathways for repair of 
therapeutic damage between malignant and normal tissues, such that ARTD/PARP 
inhibition might selectively enhance cytotoxicity from DNA damaging radiotherapy 
or chemotherapy.   
However, the exact molecular mechanisms how ARTD/PARP inhibitors act and the 
specificity of many of these compounds are not yet known [15]. ARTD/PARP 
inhibitors have been initially thought to be highly specific towards ARTD1 and 2 
(PARP1 and 2). A recent study evaluated a series of 185 small-molecule inhibitors, 
including research reagents and compounds being tested clinically, for the ability to 
bind to the catalytic domains of 13 of the 18 human ARTD family members (172). 
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These studies revealed that most of the best-known ARTD1 and ARTD2 inhibitors, 
including TIQ-A, 6(5H)-phenanthridinone, olaparib, ABT-888 and rucaparib, bind to 
several ARTD family members, including BAL2/ARTD8, BAL3/ARTD7 and 
ARTD10, strongly indicating that these molecules lack ARTD1/2 specificity and have 
promiscuous inhibitory activity (172).   
The lethal effects of ARTD/PARP inhibitors are mainly investigated in DNA repair 
deficient tumors such as triple-negative breast carcinomas, androgen-insensitive 
prostate tumors, BRCA-deficient or triple negative ovarian cancer or colon cancer 
often in combination with other DNA damaging chemotherapeutic agents (173-176). 
Only few is known whether PARP inhibitors could be also used to target other types 
tumors such as DLBCL. For instance, recent studies provided preliminary evidence 
that ARTD/PARP inhibitors can lead to an increase in cytotoxicity in mantle cell 
lymphoma harboring mutations in both ATM and p53 (177-179). 
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3. AIM OF THE THESIS 
The mayor aim of this project is to elucidate the functional roles of the intracellular 
mono-ADP-ribosyltransferase and B-aggressive lymphoma protein BAL1/ARTD9 in 
high-risk diffuse large B-cell lymphoma associated with constitutive IFN/STAT1 
signaling and to investigate whether BAL1/ARTD9 could (co)-regulate the expression 
of IFN!-dependent tumor suppressors and oncogenes in high-risk diffuse large B-cell 
lymphoma and mediate survival in diffuse large B-cell lymphoma. Thus identify new 
(lethal) regulatory connections between STAT signaling pathways and mono-ADP-
ribosylation as a potential novel therapeutic target in prostate cancer. The project 
addresses 4 different tasks: 
Task1: Does BAL1/ARTD9 regulate IFN/STAT dependent signaling in HR-  
              DLBCL ?: 
Task2:  Does BAL1/ARTD9 act as corepressor or coactivator of IFN/STAT1  
               signaling in DLBCL? 
Task3: Are the macrodomains required for the activity of BAL1/ARTD9 in  
             DLBCL?  
Task4: Does BAL1/ARTD9 mediates proliferation and survival in DLBC? 
 
Working Hypothesis: 
BAL1/ARTD9 negatively regulates IFN!/STAT1-dependent tumor suppressors such 
as IRF1, while positively regulating proto-oncogene products such IRF2 and as a 
consequence mediates survival in high-risk diffuse large B-cell lymphoma.  
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Summary
The B-aggressive lymphoma-1 protein and ADP-ribosyltransferase BAL1/ARTD9 has been recently identified as a risk-related gene
product in aggressive diffuse large B-cell lymphoma (DLBCL). BAL1 is constitutively expressed in a subset of high-risk DLBCLs with
an active host inflammatory response and has been suggested to be associated with interferon-related gene expression. Here we identify
BAL1 as a novel oncogenic survival factor in DLBCL and show that constitutive overexpression of BAL1 in DLBCL tightly associates
with intrinsic interferon-gamma (IFNc) signaling and constitutive activity of signal transducer and activator of transcription (STAT)-1.
Remarkably, BAL1 stimulates the phosphorylation of both STAT1 isoforms, STAT1a and STAT1b, on Y701 and thereby promotes the
nuclear accumulation of the antagonistically acting and transcriptionally repressive isoform STAT1b. Moreover, BAL1 physically
interacts with both STAT1a and STAT1b through its macrodomains in an ADP-ribosylation-dependent manner. BAL1 directly inhibits,
together with STAT1b, the expression of tumor suppressor and interferon response factor (IRF)-1. Conversely, BAL1 enhances the
expression of the proto-oncogenes IRF2 and B-cell CLL/lymphoma (BCL)-6 in DLBCL. Our results show for the first time that BAL1
represses the anti-proliferative and pro-apoptotic IFNc–STAT1–IRF1–p53 axes and mediates proliferation, survival and chemo-
resistance in DLBCL. As a consequence constitutive IFNc–STAT1 signaling does not lead to apoptosis but rather to chemo-resistance in
DLBCL overexpressing BAL1. Our results suggest that BAL1 may induce an switch in STAT1 from a tumor suppressor to an oncogene
in high-risk DLBCL.
Key words: BAL1/ARTD9, Diffuse large B-cell lymphoma, Macrodomains, IFNc-STAT1-signaling, Survival, ADP-ribosylation, IRF1, p53
Introduction
The B-aggressive lymphoma-1 protein and ADP-
ribosyltransferase BAL1/ARTD9, here referred to as BAL1, is
a nucleocytoplasmic shuttling protein that has been identified as
a potential risk-related gene product in diffuse large B-cell
lymphoma (DLBCL) (Aguiar et al., 2000; Juszczynski et al.,
2006). BAL1 belongs to the diphtheria-toxin-related ADP-
ribosyltransferase (ARTD) family (former PARP) of
intracellular mono- and poly-ADP-ribosyltransferases (Aguiar
et al., 2005; Aguiar et al., 2000; Hottiger et al., 2010). No auto-
modification or mono-ADP-ribosyltransferase activity has been
observed for BAL1 so far (Aguiar et al., 2005). BAL1 contains
two evolutionarily conserved macrodomains. Macrodomains
have been recently shown to act as a binding module for free
and protein-linked mono- or poly-ADP-ribose (Moyle and
Muir, 2010; Timinszky et al., 2009). BAL1 is constitutively
expressed in a subset of aggressive chemo-resistant high-risk
subtypes of DLBCL, which are associated with an active but
ineffective IFNc-mediated host inflammatory response (HR)
(Aguiar et al., 2000; Juszczynski et al., 2006). BAL1 has been
suggested to be involved in lymphocyte migration and
modulation of IFN-signaling-related gene expression in
DLBCL (Juszczynski et al., 2006). However, the exact
molecular functions of endogenous BAL1 and its regulatory
mechanisms in aggressive DLBCL have not been investigated
and remain to be elucidated.
DLBCL is a clinically heterogeneous lymphoid malignancy and
the most common subtype of non-Hodgkin’s lymphoma in adults,
with one of the highest mortality rates (Shaffer et al., 2012).
DLBCL has been subdivided into distinct classes (Rosenwald et al.,
2002; Shipp et al., 2002). Recently, a high-risk subclass with worse
clinical outcomes that is associated with an active but ineffective
host inflammatory response has been identified (Monti et al.,
2005), known as HR-DLBCL. HR-DLBCL is associated with
increased expression of inflammatory mediators and downstream
targets of interferon gamma (IFNc) signaling (Monti et al., 2005).
HR-DLBCL lacks most of the common cytogenetic abnormalities
and the exact mechanisms of transformation in these tumors
remain to be elucidated (Abramson and Shipp, 2005; Monti et al.,
2005). The clinical outcome of the HR-DLBCL cluster is not
improved, despite the increased inflammatory response
(Abramson and Shipp, 2005; Monti et al., 2005). Thus, it has
been suggested that either the host immune responses are inhibited
by counter-regulatory mechanisms or HR-DLBCL tumors are
resistant to chemotherapy, or a combination of both (Abramson
and Shipp, 2005; Monti et al., 2005).
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IFNc exhibits both pro- and anti-tumor properties, depending on
the context and cancer type (Dunn et al., 2006). Initially, IFNc
helps protect the host from tumor formation and development
(immunosurveillance), but subsequently IFNc can also promote
the tumors to resist the attack (immunoediting) (Dunn et al., 2006;
Juszczyn´ski et al., 2008; Lukacher, 2002). The anti-tumor activity
of IFNc is mediated through the signal transducer and activator of
transcription 1 (STAT1) and interferon response factor 1 (IRF1)
(Taniguchi et al., 2001). Many tumors lack IRF1 or have reduced
IRF1 expression levels (Green et al., 1999). Both STAT1 and its
mayor target gene IRF1 have been shown to positively modulate
p53-activated apoptotic pathways (Taniguchi et al., 2001;
Townsend et al., 2004). Remarkably, recent studies provided
evidence that STAT1 can also act as a proto-oncogene in solid
cancers (Khodarev et al., 2004). However, the exact molecular
mechanisms of how STAT1 acts as an oncogene are not yet known.
We have identified BAL1 as a novel co-repressor for the
transcriptional repression of tumor suppressor IRF1 and a co-
activator for the transcriptional activation of the proto-oncogenes
IRF2 and B-cell CLL/lymphoma 6 (BCL6). BAL1 interacts with
the IFNc receptor (IFNGR) complex and enhances tyrosine
phosphorylation of both isoforms of STAT1 on Y701 and their
subsequent nuclear translocation, thereby promoting the nuclear
accumulation of the antagonistically acting and transcriptionally
repressive isoform STAT1b. BAL1 interacts with both STAT1
isoforms through its macrodomains in an ADP-ribosylation-
dependent manner, and together with STAT1b inhibits the IRF1
promoter. BAL1 counteracts the IFNc-dependent anti-proliferative
and pro-apoptotic IFNc–STAT1–IRF1–p53 axes and as a
consequence, mediates proliferation, chemo-resistance and
survival in high-risk DLBCL.
Results
BAL1 is constitutively expressed in DLBCL and is
associated with aberrant IFNc/STAT1 signaling
Previous reports showed that BAL1 is constitutively
overexpressed in high-risk primary DLBCL with an active host
inflammatory response (Aguiar et al., 2005; Aguiar et al., 2000;
Juszczynski et al., 2006). Overexpression of BAL1 has also been
observed in the aggressive ABC-DLBCL cell lines OCI-Ly3 and
OCI-Ly10 as well as in the GCB-HR-like DLBCL cell line
SUDHL7 (Aguiar et al., 2005; Aguiar et al., 2000; Juszczynski
et al., 2006). IFNc/STAT1–IRF1 signaling has been shown to
stimulate the expression of BAL1 in vitro (Juszczynski et al.,
2006; Shi et al., 2011). IFNc signaling is mediated through
activation of the IFNc receptor and Janus kinases (JAK) 1 and 2
that lead to tyrosine phosphorylation of STAT1 on Y701,
homodimerization and translocation of STAT1 to the nucleus
where it induces the transcription of IFNc-stimulated genes such
as IRF1 (Dunn et al., 2006). In order to confirm these data and to
investigate whether constitutive expression of endogenous BAL1
is associated with constitutively active STAT1 signaling and
IRF1 expression we analyzed STAT1 activity in different BAL1-
expressing and -non-expressing DLBCL cell lines including the
chemo-resistant GCB-related HR-DLBCL cell line SUDHL7.
Indeed, our immunoblot analysis of BAL1, STAT1, pSTAT1,
STAT2, pSTAT2 and IRF1 expression, revealed that
constitutively expressed BAL1 is tightly associated with
intrinsic IFNc signaling and constitutively active STAT1
(Fig. 1A,B). Moreover, our STAT1-knockdown analysis using
siRNA revealed that constitutive expression of BAL1 is strictly
dependent on the transcriptional activity of STAT1 (Fig. 1C).
Subsequent chromatin immunoprecipitation analysis revealed
that endogenous STAT1 is recruited to the BAL1 promoter
(Fig. 1D), strongly indicating that STAT1 directly activates
BAL1 gene expression. STAT2 activity appears to be normal in
all DLBCL cell lines tested and not involved in upregulation of
BAL1 in HR-DLBCL cells, demonstrated by the absence of
phosphorylated STAT2. The observed IFNc-induced BAL1
expression tightly correlates with the induced activity of
STAT1 in the ABC-DLBCL cell lines OCI-Ly3 and OCI-Ly10.
However, the lower expression levels of BAL1 in OCI-Ly3 and
OCI-Ly10 could also be mediated through the constitutively high
activity of NF-kB family members in these ABC DLBCL cell
lines (Davis et al., 2010; Ngo et al., 2011; Shaffer Iii et al., 2012).
Surprisingly, tumor suppressor IRF1, a major target of STAT1
(Taniguchi et al., 2001), is strongly downregulated in the
presence of both constitutively and inducibly expressed BAL1,
whereas it is upregulated in the absence of constitutively
expressed BAL1 (Fig. 1B). These observations indicate that
BAL1 might act as a transcriptional repressor of the IRF1 gene.
Interestingly, our analysis of primary DLBCL tumors revealed
that 18% of the primary tumor samples analyzed showed positive
nuclear staining for all three analyzed markers IRF2, STAT1-
pY701 and STAT1-pS727, whereas benign tissue did not show
this pattern (Fig. 1E; supplementary material Fig. S1D,E).
BAL1 inhibits tumor suppressor IRF1 and activates
oncogenic BCL6 to mediate proliferation
In order to test whether BAL1 inhibits the tumor-suppressing
IFNc–STAT1–IRF1 axis and thus directly stimulates cell
proliferation, we first analyzed the proliferation of SUDHL7
cells in which BAL1 had been knocked down (SUDHL7-
shBAL1) and control cells (SUDHL7-shmock). Remarkably, this
experiment revealed that knockdown of BAL1 strongly inhibits
proliferation (Fig. 2A; supplementary material Fig. S2A). We
next investigated whether BAL1 is directly required for the
transcriptional downregulation of tumor suppressor genes and
upregulation of proto-oncogenes involved in proliferation and
survival in DLBCL. We first analyzed the expression levels of
the IFNc/STAT1-dependent tumor suppressors and oncogene
products such as STAT1, IRF1 and IRF2. Our results
demonstrate that the expression of tumor suppressor IRF1 is
strongly upregulated in BAL1-knockdown cells, whereas the
expression level of the proto-oncogene IRF2 is strongly reduced
(Fig. 2B,C). In contrast, the expression of STAT1 and its
isoforms is not regulated by BAL1 in SUDHL7 (Fig. 2C;
supplementary material Fig. S2B). STAT1 exists in two mayor
isoforms, the full-length isoform STAT1a, which mainly acts as a
sequence-specific activator of gene expression and STAT1b,
lacking a complete transactivation domain and acting as a
transcriptional repressor and antagonist of STAT1a (Baran-
Marszak et al., 2004; Zakharova et al., 2003). Remarkably, our
expression analysis demonstrates that BAL1 also stimulates the
expression of another IFNc/STAT1-independent crucial proto-
oncogene BCL6, while concomitantly repressing the tumor-
suppressor PR-domain-containing 1 (Prdm1) gene, the gene
product of which is the B-lymphocyte-induced-maturation
protein-1 (BLIMP1), an antagonist of BCL6 (Fig. 2B,C). The
observed transcriptional upregulation of BCL6 by BAL1 is also
consistent with previous reports demonstrating that subsets of
high-risk DLBCL are dependent on BCL6 (Saito et al., 2009).
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BCL6 is overexpressed in the majority of patients with aggressive
DLBCL (Saito et al., 2009). Constitutive expression of BCL6
mediates lymphomagenesis through aberrant proliferation and cell
survival (Saito et al., 2009). Remarkably, BAL1 also enhances the
expression of BAL2/ARTD8 and the BAL2/ARTD8 target, the
oncogenic PIM1 kinase (Cho et al., 2009a) (Fig. 2B). BAL2/
ARTD8 is another macrodomain-containing ARTD family member
(Cho et al., 2009b; Goenka and Boothby, 2006; Goenka et al., 2007).
Next we tested whether BAL1 directly regulates BCL6 and IRF1
gene expression. Indeed chromatin immunoprecipitation analysis of
SUDHL7 cells revealed that endogenous BAL1 is recruited to both
the STAT1-dependent IRF1 promoter and to the STAT1-
independent BCL6 promoter (Fig. 2D), strongly indicating that
BAL1 directly repress IRF1 gene expression and stimulates BCL6
gene expression on the level of transcriptional activation (Fig. 2D).
Activation of BCL6 tightly correlates with H4K16-acetylation and
RNA-PolII recruitment, whereas repression of IRF1 correlates with
absence of H4K16 acetylation and RNA-PolII recruitment (Fig. 2D).
In contrast, activation of PIM1 is not directly mediated by BCL1
(supplementary material Fig. S2D). As expected, STAT1 is not
required for the recruitment of BAL1 to the BCL6 promoter.
BAL1 inhibits the IRF1-mediated cell death and activates
BCL6-mediated survival
In order to test whether the observed stimulation of BCL6
expression and repression of IRF1 by BAL1 also has direct
effects on cell survival we treated SUDHL7 BAL1-knockdown
and sh-mock control cells with etoposide and/or doxorubicin and
subsequently analyzed the survival and proliferation as well as
gene expression (Fig. 3A–C). Remarkably, these experiments
revealed that BAL1 not only blocks IFNc–STAT1–IRF1-
mediated apoptosis and inhibition of growth, but also reverses
the chemo-resistance of SUDHL7 (Fig. 3A,B). Absence of BAL1
strongly increases the expression of pro-apoptotic and anti-
proliferative gene products including p21, BAD, p53 or CASP3
while simultaneously downregulating the expression of pro-
survival gene products such BCL2 or BCL-XL (Fig. 3B). IRF1
has been shown to induce both ligand-dependent (extrinsic) and
ligand-independent (intrinsic) caspase-mediated apoptosis (Stang
et al., 2007). Recent studies demonstrated that IRF1 inhibits the
expression of pro-survival members of the BCL2 family and
induces the expression and activation of pro-apoptotic and anti-
proliferative gene products, including p53, p21 and CASP3
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Fig. 1. BAL1 is constitutively expressed in
DLBCL associated with constitutively active
STAT1 signaling. (A) Immunoblot analysis of
untreated GCB-DLBCL cell lines (OCI-Ly1,
SUDHL4 and SUDHL6), ABC-DLBCL cell lines
(SUDHL2, U2932, OCI-Ly3 and OCI-Ly10) and
GCB-HR-DLBCL cell line SUDHL7. Whole-cell
extracts were separated by SDS-PAGE, blotted and
subsequently probed with antibodies for STAT1,
pSTAT1(Y701), pSTAT1(S727), STAT2,
pSTAT2(Y690), BAL1, IRF2, BCL6 and tubulin.
(B) Immunoblot analysis of STAT1 signaling in
GCB-, ABC- and HR-GCB-DLBCL cell lines
untreated or treated with 1000 U/ml IFNc for
8 hours. GCB-DLBCL cell line (SUDHL6), ABC-
DLBCL cell lines (U2932, OCI-Ly3 and OCI-Ly10)
and the GCB-HR-DLBCL cell line SUDHL7 were
untreated or treated with IFNc for 8 hours and then
whole-cell extracts separated by SDS-PAGE and
subsequently probed with antibodies for BAL1,
BAL2/ARTD8, BBAP/DTX3L STAT1,
pSTAT1(Y701), pSTAT1(S727), IRF1, BCL6 and
tubulin. (C) Immunoblot analysis of BAL1 and
STAT1 expression using whole-cell extracts of
SUDHL7-simock and siSTAT1-knockdown cells
untreated or treated with 1000 U/ml IFNc for
8 hours. (D) Chromatin immunoprecipitation (ChIP)
analysis of the BAL1 promoter for H4K16-
acetylation, STAT1, BAL1 and RNA-Pol-II
recruitment in SUDHL7 cells, using anti-STAT1,
anti-BAL1, anti RNA-Pol-II, anti-H4K16Ac and
control (Ctr) antibodies. (E) Analysis of primary
DLBCL tumors: the bars indicate the percentage of
positive nuclear staining for IRF2 alone and for all
three analyzed markers IRF2, pSTAT1(Y701) and
pSTAT1(S727) in primary DLBCL tumors and
benign samples. For a detailed description of the
scoring system see Materials and Methods and
supplementary material Tables S3, S4.
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(Choo et al., 2006; Schwartz et al., 2011; Shi et al., 2011).
Conversely, it has been previously demonstrated that BCL6 can
also suppress both the basal and the induced expression levels of
tumor-suppressor genes PRDM1/BLIMP1 and p53, the cyclin-
dependent kinase inhibitor gene p21 as well as the anti-apoptotic
proto-oncogene BCL2 in DLBCL (Phan and Dalla-Favera, 2004;
Saito et al., 2009). Interestingly, phosphorylation and inactivation
of the pro-apoptotic protein BAD is strongly reduced in absence
of BAL1 (Fig. 3B). However, phosphorylation of BAD at S112 is
probably not directly regulated by BAL1 but rather through
BAL2 and its target, the oncogenic kinase PIM1. Several studies
showed that phosphorylation of BAD on serine 112 is also
mediated by PIM1 and contributes to cell survival in B-cell
lymphoma (Aho et al., 2004; Chen et al., 2008; Yan et al., 2003).
The observed concomitant overexpression of BCL2 and BCL6
in SUDHL7 cells also indicates that BAL1 blocks BCL6-mediated
repression of the BCL2 gene, which is frequently disrupted in
DLBCL (Saito et al., 2009). We next investigated whether the
siRNA-mediated knockdown of STAT1 could inhibit the pro-
apoptotic and/or anti-proliferative pathways in absence of BAL1
and thus could rescue proliferation and/or survival in these cells.
These experiments revealed that siRNA-mediated knockdown of
STAT1 in SUDHL7 cells indeed blocks the IRF1-mediated pro-
apoptotic and anti-proliferative pathways (Fig. 3D–F). However,
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Fig. 2. BAL1 inhibits IRF1 and activates BCL6 to mediate
proliferation in DLBCL. (A) Cell proliferation analysis of
SUDHL7-parental, stable SUDHL7-shmock and BAL1-
knockdown cells over 120 hours, was assessed by a Trypan
Blue exclusion assay. Cells were seeded at 0.26106 cells/ml in
triplicate in six-well dishes and counted every day for 5 days.
Values are means 6 s.d. from three independent experiments
performed in triplicate. (B) Immunoblot analysis of tumor
suppressor gene and proto-oncogene products. Parental wild-
type SUDHL7, shmock-RNA and BCL1-shRNA knockdown
cells were untreated or treated with 1000 U/ml IFNc for 8 hours
and then whole-cell extracts separated by SDS-PAGE, blotted
and subsequently probed with antibodies for BAL1, BAL2,
STAT1, IRF1, IRF2, BCL6, BLIMP1, PIM1, PIM2 and tubulin.
(C) Gene expression analysis of stable SUDHL7 shmock RNA
and BCL1-shRNA knockdown cells. mRNAs were isolated
from transient SUDHL7 shRNA knockdown cells and BAL1,
STAT1, IRF1, IRF2, IFNGR2 and BCL6 mRNA levels were
measured by qPCR and normalized against GAPDH. (D) ChIP
analysis of IRF1 and BCL6 promoters for H4K16-acetylation,
STAT1, BAL1 and RNA-Pol-II recruitment in SUDHL7 cells
using anti-STAT1, anti-BAL1, anti RNA-Pol-II, anti-H4K16Ac
and control (Ctr) antibodies.
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the observed proliferation defects and increased cell death in
siBAL1 cells could not be fully rescued in presence of siSTAT1
RNA, indicating first that STAT1 itself is required for survival and
proliferation, most probably through IRF2, and second, the
presence of overexpressed BCL6 is equally important for
survival in this cell line (Fig. 3D–F).
BAL1 forms complexes with STAT1a and STAT1b through
its macrodomains and is recruited by STAT1 to its
target promoters
Since tumor suppressor IRF1 is a major target of STAT1 we
investigated whether BAL1 could form a complex with STAT1
or other IFN-related STAT members in vivo. We first performed
co-immunoprecipitation experiments with HA-tagged BAL1 and
FLAG-tagged STAT1-6 transiently coexpressed in HEK293
cells, as well as with endogenously expressed BAL1 and
STAT1 in SUDHL7 cells. Our interaction studies revealed that
BAL1 specifically interacts with both STAT1 and STAT2
(Fig. 4A), indicating that endogenous BAL1 forms complexes
with both IFNc-induced STAT1 homodimers (Fig. 4B).
Moreover, BAL1 interacts with both STAT1a and STAT1b
isoforms (Fig. 4C). No interaction between BAL1 and other
STATs (STAT3–6) could be observed under the tested conditions
(Fig. 4A). We next tested which domain of BAL1 is required for
the observed interaction by performing co-immunoprecipitation
experiments with HA-tagged full-length BAL1 and deletion
mutants coexpressed together with FLAG-tagged STAT1 or
STAT2 in HEK293 cells. Remarkably, these mapping
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Fig. 3. BAL1 inhibits the IRF1-mediated pro-
apoptotic pathways and activates the BCL6-
mediated survival pathways. (A) Cell
proliferation analysis of parental SUDHL7 cells,
stable SUDHL7 shmock and BAL1-knockdown
cells treated with etoposide (Etopo; 25 mM) and/or
doxorubicin (Doxo; 5 mM) was assessed by a
Trypan Blue exclusion assay. Cells were seeded at
0.26106 cells/ml in triplicate in six-well dishes,
treated as indicated and counted every day for 5
days. Values are means 6s.d. from three
independent experiments performed in triplicate.
(B) Immunoblot analysis of pro-apoptotic and
survival factors. SUDHL7 shmock-RNA and
BAL1-shRNA knockdown cells were untreated or
treated with Etoposide (25 mM) for 24 hours and
then whole-cell extracts separated by SDS-PAGE,
blotted and subsequently probed with antibodies
for BAL1, BCL2, BCL-xL, PIM1, BAD, pBAD-
S112, p53, p21, Casp3, cleaved Casp3 and tubulin.
(C) Cell viability analysis of parental SUDHL7
cells, stable SUDHL7 shmock and BAL1-
knockdown cells untreated (control, c) treated with
etoposide (E; 25 mM) and/or doxorubicin (D;
5 mM) was assessed by a Trypan Blue exclusion
assay. Cells were seeded at 0.26106 cells/ml in
triplicate in six-well dishes, treated as indicated
and counted every day for 5 days. Values aremean
percentages from three independent experiments
performed in triplicate. (D) Cell proliferation
analysis of untreated SUDHL7-si mock, siBAL1,
siSTAT1 and siSTAT1/BAL1 knockdown cells.
(E) Cell viability analysis of SUDHL7-simock,
siBAL1, siSTAT1 and siBAL1/siSTAT1-
knockdown cells untreated (control, c) or treated
with etoposide (25 mM) and doxorubicin (5 mM)
was assessed by a Trypan Blue exclusion assay.
Cells were seeded at 0.26106 cells/ml in triplicate
in six-well dishes, treated as indicated and counted
every day for 5 days. Values are means from three
independent experiments performed in triplicate.
(F) Immunoblot analysis of siSTAT1 knockdown
cells. SUDHL7 simock-RNA, STAT1-siRNA and
STAT1-siRNA/BAL1-siRNA knockdown cells
were untreated or treated with Etoposide (25 mM)
for 24 hours and then whole cell extracts separated
by SDS-PAGE, blotted and subsequently probed
with antibodies for STAT1, BAL1, IRF1, IRF2
and BCL6.
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experiments revealed that the observed interactions between
BAL1 with STAT1 are mediated through both macrodomains
(Fig. 4D; supplementary material Fig. S3A) and thus might
be dependent on n-ADP-ribosylation. Subsequent co-
immunoprecipitation experiments revealed that the interaction
is indeed mediated by (mono)-ADP-ribosylation (Fig. 4E). Thus,
our results suggest a potential regulatory connection between
ADP-ribose binding modules and mono-ADP-ribosylation-
dependent signaling and gene expression in high-risk DLBCL
and other B-cell lymphomas. STAT1 is modified in vitro by
BAL2/ARTD8 and ARTD10 (data not shown). However, we
were unable to elucidate the exact mechanisms in vivo and thus
we have no evidence so far that STATs are ADP-ribosylated in
vivo. Analyzing protein mono-ADP-ribosylation in vivo is a
difficult task because antibodies specifically recognizing mono-
ADP-ribosylated glutamate or arginine residues are lacking and
ADP-ribosylation of proteins in vivo is not easily analyzed by
mass spectrometry (Hottiger et al., 2010). Moreover, there are no
ARTD-family-member-specific ARTD/PARP inhibitors
available that would specifically target BAL2, BAL3 or other
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Fig. 4. See next page for legend.
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mono-ADP-ribosylating ARTD family members (Hottiger et al.,
2010; Wahlberg et al., 2012). We could not observe any effects
on STAT1-dependent signaling and gene expression using
Olaparib or Veliparib, two ARTD/PARP inhibitors highly
specific to ARTD1 and ARTD2 (data not shown), also
indicating that the enzymatic activity of ARTD1 and/or
ARTD2 is not required for these BAL1/ARTD9-dependent
processes.
Recent studies showed that overexpression of STAT1b, the
antagonistic isoform of STAT1a increases the growth rate of
cells and their resistance to drug-induced apoptosis and cell cycle
arrest by repressing STAT1a target genes such as p21 and IRF1
in human B cells (Baran-Marszak et al., 2004). We therefore
performed IRF1-promoter-driven luciferase reporter assays with
BAL1, STAT1a and STAT1b, in the BAL1-negative DLBCL cell
line U2932 (Fig. 4F). Indeed, coexpression of BAL1 wild-type or
macrodomain deletion mutants together with STAT1a or
STAT1b, respectively, along with an IRF1-promoter driven
luciferase reporter in U2932 cells showed that overexpression
of BAL1 wild-type together with STAT1b synergistically
downregulated the IRF1-promoter driven luciferase reporter
upon IFNc stimulation, even in presence of STAT1a, whereas
no BAL1-mediated repression was observed with BAL1-
macrodomain deletion mutants, suggesting that the observed
inhibitory effect is directly mediated through the macrodomain-
dependent interaction of BAL1 with STAT1b (Fig. 4F). Next we
tested whether STAT1 is required for the recruitment of BAL1 to
its STAT1-dependent target promoters. Indeed chromatin
immunoprecipitation analysis in A549 cells ectopically
expressing HA-tagged BAL1 independent of STAT1
(supplementary material Fig. S3B,C) revealed that the
recruitment of BAL1 to the IRF1 promoter is strictly dependent
on STAT1 (Fig. 4G,H).
BAL1 stimulates the phosphorylation and nuclear
translocation of STAT1
We next investigated whether BAL1 could modulate the balance
between transcriptionally active STAT1a and transcriptionally
repressive STAT1b complexes in the nucleus through stimulation
of STAT1a and STAT1b phosphorylation on tyrosine 701. Indeed,
our phosphorylation analysis revealed that BAL1 stimulates the
phosphorylation of both STAT1a and STAT1b on Y701 but not on
serine 727 of the transcriptionally activating isoform STAT1a
(Fig. 5A). IFNGR–JAK2-mediated phosphorylation of STAT1 on
Y701 is required for STAT1 dimerization and its nuclear
translocation (Darnell et al., 1994; Mowen and David, 2000).
Phosphorylation on Y701 also enhances the nuclear shuttling by
triggering the nuclear retention of the shuttling STAT1a and
STAT1b, which are kept in the nucleus until tyrosine
dephosphorylation occurs (Meyer et al., 2003). JAK2 is thought
to phosphorylate STAT1 on Y701 in the cytoplasm, whereas JAK1
seems to be required for phosphorylation on Y701 in the nucleus,
preventing nuclear export of STAT1 (Meyer et al., 2003; Mowen
and David, 2000). However, phosphorylation on S727 in the
transactivation domain of STAT1a can also occur independently
of STAT1 tyrosine phosphorylation (Decker and Kovarik, 2000).
BAL1 might, therefore, mainly influence the shuttling kinetics
of STAT1. Our subsequent subcellular fractionation analysis
confirmed that BAL1 is indeed required for the constitutive
exclusively nuclear localization of STAT1 in HR-DLBCL
(Fig. 5B). Finally, our co-immunoprecipitation analysis
revealed that BAL1 interacts with the IFNGR1 complex but
not with the pY701-specific tyrosine phosphatase PTBN1 in HR-
DLBCL (Fig. 5C), indicating that BAL1 may directly stimulate
JAK2-mediated phosphorylation of STAT1 and thereby promote
the nuclear accumulation of the antagonistically acting and
transcriptionally repressive isoform STAT1b. Remarkably, a
recent study provided the first evidence that the BAL1-related
BAL2/ARTD8 promotes the survival of myeloma cells by
inhibiting the kinase activity of c-Jun N-terminal kinase 1
(JNK1) (Barbarulo et al., 2012). Since phosphorylation of
STAT1a on S727 is not affected by BAL1, our results indicate
that BAL1 influences the nuclear activities of the
transcriptionally repressive isoform STAT1b thereby tipping
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Fig. 4. BAL1 forms an ADP-ribosylation-dependent complex with STAT1
and represses the IRF1 promoter together with STAT1b. (A) Co-
immunoprecipitation of BAL1 and STATs overexpressed in HEK293 cells.
HEK293 cells were co-transfected with expression vectors for HA-tagged
BAL1 full length along with FLAG-tagged STAT1, STAT2, STAT3, STAT4,
STAT5 or STAT6 and subsequently stimulated for 1 hour with 1000 U/ml
IFNc. HA–BAL1 and STAT1 complexes were then co-immunoprecipitated,
separated on SDS-PAGE, blotted and subsequently probed with antibodies for
HA (BAL1) and FLAG tag (STATs). (B) Interaction of endogenous BAL1 and
STAT1 is partially dependent of IFNc. SUDHL7 cells were stimulated for
1 hour with 1000 U/ml IFNc and endogenous BAL1 and STAT1 complexes
subsequently co-immunoprecipitated using an anti-BAL1 antibody. Complexes
were then separated on SDS-PAGE, blotted and probed with antibodies against
endogenous BAL1 and STAT1. (C) BAL1 interacts with both isoforms of
STAT1. HEK293 cells were co-transfected with expression vectors for HA-
tagged BAL1 full length along with FLAG-tagged STAT1a or STAT1b and
subsequently stimulated for 1 hour with 1000 U/ml IFNc. HA–BAL1 and
STAT1 complexes were then co-immunoprecipitated, separated on SDS-
PAGE, blotted and probed with antibodies for HA (BAL1) and FLAG tag
(STATs). (D) Mapping of the interaction domains in BAL1. HEK293 cells were
co-transfected with expression vectors for HA-tagged BAL1 full length, or
deletion mutants [deletion of macro domain 1 and 2 (Dm1 and Dm2) or
catalytic domain (DCD)] along with FLAG-tagged STAT1, and subsequently
stimulated for 1 hour with 1000 U/ml IFNc. HA–BAL1 and STAT1 complexes
were then co-immunoprecipitated, separated on SDS-PAGE, blotted and
probed with antibodies for HA (BAL1) and FLAG tag (STAT1). (E) Co-
immunoprecipitation of endogenous BAL1 and STAT1 in the presence of
ADP-ribose. SUDHL7 cells were stimulated for 1 hour with 1000 U/ml IFNc
and endogenous BAL1 and STAT1 complexes were subsequently co-
immunoprecipitated in the presence of increasing concentrations of ADP-ribose
(0.01–1 mM) using an anti-BAL1 antibody. BAL1-STAT1 complexes were
then separated on SDS PAGE, blotted and subsequently probed with antibodies
against endogenous BAL1 and STAT1. (F) BAL1 inhibits the IRF1-promoter-
driven luciferase in U2932 cells. BAL1-negative U2932 cells were seeded in
12-well dishes at 0.46106 cells/ml and co-transfected with an IRF1-promoter-
driven luciferase reporter vector (500 ng DNA/ml) along with expression
vectors for BAL1 wild type, 3x-NLS-BAL1 wild type or BAL1-macrodomain
deletion mutants (BAL1Dm1 or BAL1Dm2), STAT1a (first and middle left) or
STAT1b (middle left, middle right and right panels; 800 ngDNA/ml) and with
the control reporter plasmid, pRL-hTK (100 ng/ml; TK-Renilla–luciferase
control, Promega). The cells were then treated with 1000 U/ml IFNc for
10 hours or left untreated. IRF1-promoter-Luciferase activities are normalized
to the luciferase activities of the internal TK-Renilla–luciferase control and
presented as means from 5 independent experiments performed in triplicate 6
standard deviations. (G) ChIP analysis of IRF1 promoter for H4K16-
acetylation, STAT1, HA–BAL1 and RNA-Pol-II recruitment in si-mock- and
siSTAT1-RNA-treated A549 knockdown cells ectopically expressing HA-
tagged BAL1 using anti-STAT1, anti-HA, anti RNA-Pol-II, anti-H4K16Ac and
control (Ctr) antibodies. (H) IRF1 gene expression analysis in A549 control
cells and A549 cells ectopically expressing HA-tagged BAL1. IRF1 mRNA
levels were measured by qPCR and normalized against GAPDH.
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the antagonistic balance between STAT1 dimers activating
transcription and STAT1 dimers repressing transcription.
Discussion
In this study, we identified BAL1/ARTD9 acting as a novel IFNc-
specific oncogenic survival factor in high-risk DLBCL. We further
showed that constitutive overexpression of BAL1 in DLBCL
tightly associates with intrinsic IFNc signaling and constitutive
nuclear activity of STAT1. BAL1 counteracts the IFNc-dependent
anti-proliferative and pro-apoptotic IFNc–STAT1–IRF1–p53 axis
while concomitantly activating IFNc/STAT1-dependent (i.e.
IRF2-mediated) and IFNc/STAT1-independent (i.e. BCL6/
BCL2-mediated) anti-apoptotic-pro-survival pathways. As a
consequence, overexpression of BAL1 in HR-DLBCL mediates
cell proliferation chemo-resistance and survival in high-risk
DLBCL. The observed inhibition of tumor suppressor IRF1 and
simultaneous upregulation of the proto-oncogenes IRF2, BCL2 and
BCL6 by BAL1 strongly correlates with the phenotype of high risk
DLBCL in vitro and the clinical outcome of HR-DLBCL
(Abramson and Shipp, 2005; Monti et al., 2005).
IRF1 mediates anti-proliferative and pro-apoptotic effects in
cancer cells in a context-dependent and cell-type-specific manner
(Choo et al., 2006). In the absence of antagonistic regulatory
factors, increased expression and activation of IRF1 inhibits the
expression of pro-survival members of the BCL2 family and
simultaneously induces the expression and activation of pro-
apoptotic and anti-proliferative gene products, including p53, p21
and CASP3 (Choo et al., 2006; Schwartz et al., 2011; Shi et al.,
2011). IRF2, an antagonist of IRF1 is known to act as an
oncogene product in various types of cancer and when
overexpressed in cancer, IRF2 can abolish the tumor
suppression function of IRF1 (Choo et al., 2006). Although loss
of IRF1 alone is not associated with spontaneous tumor
development in mice, it greatly increases tumor susceptibility
in combination with loss of other tumor suppressor proteins such
as p53 (Nozawa et al., 1999). On the other hand, it has been
previously demonstrated that BCL6 can also suppress both, the
basal and the induced expression levels of tumor suppressors p53
and the cyclin-dependent kinase inhibitor p21 (Phan and Dalla-
Favera, 2004; Saito et al., 2009). Loss or mutation of p53 are
observed in about 20% of patients with high risk DLBCL and
have statistically significant negative impact on progression-free
survival (Stefancikova et al., 2011). Loss or mutation of p53 is
associated with a shorter survival after R-CHOP treatment
(Stefancikova et al., 2011). Thus the observed BAL1-mediated
downregulation of tumor-suppressors IRF1 and simultaneous
upregulation of BCL6 represents another molecular mechanism
inactivating the p53/IRF1 pro-apoptotic pathway in high-risk
DLBCL-expressing wild-type p53.
Remarkably, our study provides the first evidence that BAL1 not
only blocks IFNc–STAT1–IRF1-mediated apoptosis and inhibition
of growth, but also reverses the chemo-resistance in high-risk
DLBCLs. Our results also strongly indicate that STAT1 acts as an
oncogene in high-risk HR-DLBCLwith an active host inflammatory
response. This activity is at least partially mediated by BAL1. BAL1
facilitates the oncogenic functions of STAT1 by counteracting the
pro-apoptotic IFNc–STAT1–IRF1 axis. Moreover, together with
STAT1b, BAL1 may negatively regulate a tumor suppressor
network, thereby inducing a switch in STAT1 from a tumor
suppressor to an oncogene. This also explains why constitutive
IFNc–STAT1 signaling does not lead to apoptosis but rather to
survival and chemo-resistance in HR-DLBCL (Fig. 6). Recent
studies showed that aberrant nuclear localization and activity of
STAT1 leads to radio- and chemo-resistance in solid cancers
(Khodarev et al., 2004; Khodarev et al., 2009; Khodarev et al., 2012;
Stronach et al., 2011; Weichselbaum et al., 2008).
Strikingly, our studies also demonstrate that BAL1 interacts
with the IFNGR complex and enhances tyrosine phosphorylation
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Fig. 5. BAL1 specifically stimulates the
phosphorylation of STAT1a and STAT1b on Y701.
(A) Immunoblot analysis of STAT1 signaling in
SUDHL7-shmock and -BAL1-knockdown cells. Parental
wild-type SUDHL7, shmock-RNA and BAL1-shRNA
knockdown cells were untreated or treated with 1000 U/
ml IFNc for 8 hours and then whole-cell extracts were
separated by SDS-PAGE, blotted and probed with
antibodies for BAL1, STAT1, pSTAT1(Y701),
pSTAT1(S727), JAK1, pJAK1, JAK2, pJAK2, PTPN1,
PTPN2 and tubulin. (B) Subcellular fractionation
analysis of STAT1 signaling in SUDHL7-shmock and
BAL1-shRNA knockdown cells. The cells were
untreated or treated with 1000 U/ml IFNc for 8 hours
and then nuclear and cytoplasmic cell extracts were
separated by SDS-PAGE, blotted and probed with
antibodies for BAL1, STAT1, pSTAT1(Y701),
pSTAT1(S727), ARTD1(PARP1) and tubulin. (C) Co-
immunoprecipitation analysis of endogenous BAL1-
tyrosine-kinase/-phosphatase complexes in SUDHL7
cells. Endogenous BAL1/IFNGR complexes were co-
immunoprecipitated using an anti-BAL1 antibody.
Complexes were then separated by SDS-PAGE, blotted
and probed with antibodies against endogenous BAL1,
IFNcR1, pJAK1, pJAK2 and PTPN1.
Journal of Cell Science 126 (0)8
of both STAT1 isoforms, STAT1a and STAT1b, on Y701, and
their subsequent nuclear translocation, thereby promoting the
nuclear accumulation of the antagonistically acting and
transcriptionally repressive isoform STAT1b. Thus, BAL1
influences the nuclear activities of the transcriptionally
repressive isoform STAT1b, tipping the antagonistic balance
between STAT1 dimers activating transcription and STAT1
dimers repressing transcription. However, the exact molecular
mechanism(s) underlying the isoform- and promoter-specific
regulation of STAT1 by BAL1 remain to be elucidated in future
studies. Unfortunately, the specific antagonistic nuclear activities
of STAT1a and STAT1b, and their distinct phosphorylated and
unphosphorylated forms in particular, are in general not very well
investigated yet.
In contrast, BCL6 is not likely to be a direct target gene of
STAT1, so the observed BAL1-mediated stimulation of BCL6
expression might be caused by another unknown mechanism.
BCL6 overexpression is mediated through multiple mechanisms
in DLBCL: translocation, hypermutation of its promoter, or
inactivation of FBXO11, which results in increased levels and
stability of BCL6 (Duan et al., 2012). Transcriptional
upregulation of BCL6 by BAL1, therefore, represents an
additional molecular mechanism for overexpression of BCL6 in
DLBCL. Moreover, the observed concomitant overexpression of
BCL2 and BCL6 in SUDHL-7 cells also indicates that BAL1
could block BCL6-mediated repression of the BCL2 gene, which
is frequently disrupted in DLBCL (Saito et al., 2007; Saito et al.,
2009). However, the exact STAT1-independent molecular
mechanisms involved in BAL1 stimulation of the
transcriptional activation of BCL6 and BCL2 have to be
thoroughly investigated in future.
Finally our study provides the first evidence for an IFNc-
dependent STAT1–BAL1–BCL6-mediated anti-apoptotic-, pro-
survival-regulatory circuit in HR-DLBCL and explains why
STAT1 could function as an oncogene in a subset of HR-
DLBCL. In addition, our observations could also provide a
molecular mechanism for the risk-related activity of BAL1 in
HR-DLBCL subsets without constitutive active STAT1
signaling. BAL1 could be directly involved in editing or
inhibiting the IFNc-dependent host immune response against
HR-DLBCL through the termination of IFNc-mediated gene
expression and inhibition of the extrinsic IFNc-induced
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Fig. 6. Model for the BAL1-mediated oncogenic switch in STAT1 in HR-DLBCL. (A) Constitutively active IFNcR-JAK1/2-STAT1 signaling in HR-DLBCL
causes overexpression of BAL1, which in turn further stimulates the phosphorylation of STAT1 on Y701 and subsequently the enhanced expression of STAT1a-
dependent proto-oncogenes (i.e. BBAP/BAL1, BAL2, IRF2). Conversely, BAL1 together with STAT1b represses the transcriptional activation of tumor suppressor
IRF1. In addition, overexpression of BAL1 also enhances the expression of STAT1-independent proto-oncogenes (i.e. BCL6). (B) Overexpression of BAL1
prevents intrinsic and extrinsic IFNc-STAT1-IRF1/p53-mediated cell death pathways while simultaneously enhancing the STAT1-dependent IRF2-mediated
proliferation and STAT1-independent BCL6–BCL2-mediated survival pathways. As a consequence BAL1 induces an switch in STAT1 from a tumor suppressor
to an oncogene and mediates proliferation, survival and chemo-resistance in HR-DLBCL. (C) Inactivation of BAL1 in HR-DLBCL associated with constitutively
active STAT1 signaling reactivates the anti-proliferative and pro-apoptotic IFNc-STAT1-IRF1/p53 axes and reverses chemo-resistance in
HR-DLBCL.
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anti-proliferative and pro-apoptotic STAT1–IRF1–p53 axes.
The observed macrodomain and ADP-ribosylation-mediated
interaction between BAL1 and STAT1 as well as the BAL1-
mediated upregulation of BAL2/ARTD8 also indicates a regulatory
cross talk between BAL1 and other active members of the ARTD
family such as BAL2/ARTD8 or ARTD10 in these processes.
BAL2/ARTD8 is a macrodomain-containing ARTD familymember
and an active mono-ADP-ribosyltransferase mediating survival in c-
Myc-driven Burkitt lymphoma-like tumor cells in vivo (Cho et al.,
2009a). BAL2/ARTD8 has been suggested to function as a STAT6-
specific co-regulator of IL-4-mediated gene expression and has been
suggested to be involved in mediating IL-4-induced proliferation
and protection of B-cells against apoptosis following irradiation or
growth factor withdrawal (Cho et al., 2009b; Goenka and Boothby,
2006; Goenka et al., 2007).
Together, our studies further strengthen the hypothesis that
BAL1 may serve as a novel potential drug target for treatment of
high-risk chemo-resistant diffuse large B-cell lymphoma. The
combination of classic therapeutic drugs with novel drugs
targeting STAT1 or the macrodomains of BAL1/ARTD9 might
be a strategy to increase the sensitivity of HR-DLBCL towards
classic therapy, and thus pave the way to develop novel
therapeutic strategies for the remainder of DLBCL patients
suffering from aggressive chemo-resistant high-risk host
response variants of DLBCL.
Material and Methods
Cell culture, transfections, luciferase reporter assays and generation of
stable cell lines
The human lung carcinoma cell line A549, 293HEK and DLBCL cell lines were
cultured as described previously (Hassa et al., 2005; Saito et al., 2009). The
DLBCL cell lines SUDHL2, SUDHL4, SUDHL6, SUDHL7, U2932, OCI-Ly1,
OCI-Ly3 and OCI-Ly10 were provided by Dr Riccardo Dalla-Favera (Columbia
University, NY, USA), Dr Jose Martinez-Climent (Spanish National Cancer
Research Centre, Madrid, Spain) and Dr Louis Staudt (National Institutes of
Health, Bethesda, MD, USA). 293HEK were purchased from ATCC.
Transfections of cells with plasmid DNA (for reporter assays and generation of
stable cell lines) were performed with Fugene HD, Extreme gene 9 and HP
transfection reagents (Roche Applied Science) according to the manufacturer’s
protocols. Stable cell lines were generated using a Piggyback transposon and a
BIC-miR155-precurser-RNA based shRNA-expressing system. Piggyback-
transposed cells were selected with puromycin (500 ng/ml). Transfections of
siRNA oligos (40 pmol siRNA/transfection) were performed with Lipofectamine
RNAimax reagent (Invitrogen) or Extreme gene siRNA (Roche Applied Science)
according to manufacturers’ protocols. Luciferase reporter assays were performed
as previously described (Hassa et al., 2005) and according to manufacturer’s
protocols (Promega) using the Dual Luciferase assay kit (Promega) and a TECAN
infinite M200 luminometer (Tecan Systems).
Plasmids
Human BAL1/ARTD9 cDNA was amplified by PCR from a B-cell lymphoma
cDNA library and cloned into the corresponding expression vectors (pcDNA-HA-,
pPiggyBac-EF1aprom-HA-BAL1) using NheI–NotI or NotI, respectively. BAL1-
domain deletion and GST-fusion constructs were generated by PCR and cloned into
the NheI–NotI or EcoRI–NotI sites of pcDNA-HA- and pETM-GST-MCS1,
respectively. All constructs and full-length cDNA sequences were verified by
sequencing. All empty basic Piggyback transposon vectors and expression vectors
for the latest version of Piggyback transposases were either purchased from System
Biosciences (SBI) Inc. (Mountain View, CA, USA) or provided by Dr Allan Bradley
(WellcomeTrust Sanger Institute, UK). The BIC-mir155 vector system (Chung et al.,
2006) was provided by Dr David L. Turner (Molecular and Behavioral Neuroscience
Institute, University of Michigan, Ann Arbor, USA). The siRNA and shRNA/DNA
oligos were purchased from Qiagen. The corresponding siRNA and shRNA
sequences are listed in supplementary material Table S1. FLAG–STATs were
purchased from Addgene. hIRF1-prom-luciferase reporter vectors were a gift from
Dr R. Pine (Public Health Research Institute, Newark, NJ, USA).
Reagents
Human recombinant IFNc was purchased from PeproTech, doxorubicin and
etoposide were purchased from Sigma. Tosyl-//activated Dynabeads were
purchased from Invitrogen. ADP ribose was purchased from Sigma. High-
performance glutathione–Sepharose and Ni-Sepharose were purchased from
Amersham Biosciences.
Gene expression analysis
Real-time qPCR analysis was performed essentially as described previously
(Guetg et al., 2012). Total RNA was isolated using Trizol (Invitrogen) or Tri-
Reagent (MRC Inc.) according to manufacturers’ protocols. RNA was
subsequently reverse-transcribed using the ‘High-Capacity cDNA Reverse
Transcription kit’ (Applied Biosystems) according to manufacturer’s protocols.
Real-time qPCR was performed using the Rotor-Gene 3000 (Corbett Life
Science, now Qiagen) and SYBR Green kit (Bioline) according manufacturers’
protocols using the primers listed in supplementary material Table S2. Mean
values 6 s.e.m. were calculated and plotted as graphs with GraphPad Prism
(GraphPad Software).
Chromatin immunoprecipitation
Cells were collected and crosslinked with 1% formaldehyde as described
previously (Covic et al., 2005). Chromatin fragmentation was achieved with the
Bioruptor (Diagenode). Antibodies were incubated with crosslinked chromatin
overnight at 4 C˚ and collected with Protein-A agarose/salmon sperm DNA
(Millipore) for 3 hours. After reversal of the crosslinking and digestion with
proteinase K, DNA was extracted and measured by real-time PCR using SYBR
Green and the Rotor-Gene 3000 (Corbett Life Science/Qiagen).
Expression, purification of recombinant proteins
Recombinant HIS–GST–BAL1 fusion proteins were expressed in E. coli strains
BL21 DE3-Rosetta-II, BL21 DE3-Rosetta-II-Tuner and BL21-ArcticExpress-
Rosetta-II as described previously (Timinszky et al., 2009). All purified proteins
were analyzed using Coomassie Blue staining and confirmed by western blot
analysis using the corresponding antibodies.
Interaction assays, immunoblot analysis and immunofluorescence
microscopy
Membrane, cytoplasmic, nuclear and whole-cell extracts were prepared as
described previously (Cunningham et al., 2003; Dignam et al., 1983; Hassa et al.,
2005; Okada et al., 2008; Sen et al., 2011) with minor modifications: membrane
extraction buffer contain 50 mM HEPES (pH 7.9) 150 mM sodium chloride, 1%
Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 2.5 mM sodium
pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4 1 mM EDTA, 1 mM
EGTA and cOmplete, EDTA-free Protease Inhibitor Cocktail (Roche). For
immunoprecipitation, membrane and cytoplasmic extract fractions were re-mixed.
Co-immunoprecipitation and GST pull-down assays were performed as described
previously (Hassa et al., 2005; Owen et al., 2005; Timinszky et al., 2009), except
that the antibodies used for immunoprecipitation were covalently coupled to tosyl-
activated Dynabeads (Invitrogen) according to the manufacturer’s protocols.
Immunoprecipitation buffers contained 80 mM Tris (pH 7.05), 125 mM NaCl,
25 mM potassium acetate, 1.5 mM MgCl2, 5% glycerol, 0.5% NP-40, 0.5 mM
DTT, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 0.1 mM
Na3VO4, and cOmplete, EDTA-free Protease Inhibitor Cocktail (Roche). GST
pull-down buffers contained 80 mM Tris (pH 7.05), 1.5 mM MgCl2, 150 mM
NaCl, 50 mM potassium acetate, 0.5% NP-40, 0.5 mM DTT, 2.5 mM sodium
pyrophosphate, 1 mM b-glycerophosphate, 0.1 mM Na3VO4, 5% glycerol and
cOmplete, EDTA-free Protease Inhibitor Cocktail (Roche). Immunoblot
procedures and immunofluorescence microscopy were performed as described
previously (Guetg et al., 2012; Hassa et al., 2005) using the following primary
antibodies: monoclonal mouse anti-HA and mouse anti-FLAG antibodies (both
Sigma), polyclonal rabbit anti-BAL1 antibodies (C-terminal; Millipore),
monoclonal rabbit anti-STAT1, anti-pSTAT1(Y701), anti-pSTAT1(S727), anti-
STAT2, anti-pSTAT2(Y690), anti-IRF2, anti-BLIMP1, anti-Casp3, anti-BCL2,
anti-BAD, anti-BAD-S112, anti-PIM1, anti-PIM2, anti-PTBN1, anti-JAK1, anti-
pJAK1, anti-JAK2, anti-pJAK2, anti-IFNGR1, anti-PTBN2 and anti-BCL-XL
antibodies (RabMab, Epitomics), monoclonal rabbit anti-IRF1 (RabMab, Cell
Signaling Technology), monoclonal mouse anti-tubulin, polyclonal rabbit anti-p53
and anti-BCL6 antibodies (Santa Cruz Biotechnology). The polyclonal rabbit anti-
BAL2/ARTD8 antibody was a generous gift from Avraham Raz (Karmanos
Cancer Institute, School of Medicine, Wayne State University, Detroit, Michigan
48201, USA) (Yanagawa et al., 2007). Immunofluorescently stained cells were
analyzed by fluorescence microscopy on a Leica DMI6000B automated inverted
research microscope system (Leica Microsystem). Composite images were
generated using Adobe Photoshop software.
Flow cytometry analysis, survival and proliferation assays
FACS analysis was performed with the following PE-conjugated antibodies
(Biolegend) according to manufacturer’s protocols: PE anti-human CD119 (IFNcR
a-chain) PE anti-human CD40, PE Syrian hamster IgG isotype control and PE
mouse IgG2 isotype control antibodies. PE-positive and PE-negative cells were
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sorted using a BD FACSVantage cell sorter flow cytometer (BD Biosciences). Cell
viability and proliferation were assessed by Trypan Blue exclusion and by the
WST1 assays (Roche Diagnostics) according to manufacturers’ protocols. For the
cell viability and proliferation assays cells were seeded at 0.26106 cells/ml in six-
well dishes 8 hours prior to initiation of treatment and then incubated in the
presence of PBS, DMSO (mock-treated), etoposide (20 mM) or doxorubicin
(2 mM) for 24 hours. After 24 hours the cultures were washed with medium prior
to reseeding in fresh medium for continued culture (24, 48, 72 and 96 hours).
Relative cell viability/proliferation and cell numbers are presented as means from
three independent experiments performed in triplicate 6 standard deviations.
Analysis of tissue samples
In total, 250 formalin-fixed and paraffin-embedded tissue samples were analyzed,
which consisted of 12 tonsils with reactive lymphoid hyperplasia and 238 diffuse
large B-cell lymphomas (DLBCL). Histopathological diagnosis was rendered
according to the World Health Organization classification. Two cores of 0.1 cm
diameter were punched out of each sample of the respective donor blocks and
transferred to Tissue-Micro-Array recipient blocks, from which 3 mm thick
sections were cut and mounted on Superfrost slides (Menzel Glaser). The primary
antibodies used were anti-pSTAT1(Y701) (rabbit polyclonal, Cell Signaling
Technology, dilution 1:25 in Ventana Buffers), anti-pSTAT1(S727) (rabbit
monoclonal, Epitomics Inc., dilution 1:400 in Ventana Buffers) and anti-IRF2
(rabbit monoclonal, Epitomics Inc., dilution 1:50 in Ventana Buffers). Staining
was performed with the Ventana Discovery Ultra automated staining system
(Ventana Medical Systems Inc.), operated according to the manufacturer’s
instructions and using solely Ventana reagents during the procedure. Detection
was performed with the ChromoMap DAB detection kit using Ultra Map Anti Rb
HRP. Negative controls were performed by omission of the primary antibodies.
Slides were counterstained with Hematoxylin, dehydrated and mounted. Staining
intensity was assessed with a light microscope, allocating a semi-quantitative score
to each core. For all three markers, the approximate percentage of stained nuclei
was recorded. The scoring was undertaken as follows: ,10% was scored as 1, 10–
50% as 2, 50–80% as 3 and .80% as 4; negative staining was scored as 0. Scoring
was omitted for cores not containing appropriate tissue or in cores with artifacts
resulting from crushing (see also supplementary material Tables S3, S4).
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4.2 Unpublished results 
4.2.1 BAL1/ARTD9 inhibits the nuclear translocation of tumor suppressor IRF1 
Since BAL1/ARTD9 is a nucleo-cytoplasmic shuttling protein, we next investigated 
whether BAL1/ARTD9 could also regulate the sub-cellular localization of IRF1. 
Surprisingly, immuno-fluorescence analysis for BAL1/ARTD9 and IRF1 in 
SUDHL7-BAL1/ARTD9-shRNA knockdown cells revealed that BAL1/ARTD9 could 
also repress IRF1 at the level of nuclear translocation (Figure 8A). The remaining 
poorly expressed IRF1 in parental and si-mockRNA transfected SUDHL7 cells does 
not translocate to the nucleus and accumulates in the cytoplasm upon IFN! 
stimulation (Figure 8A). Conversely IRF1 localizes to the nucleus in absence of 
BAL1/ARTD9 in SUDHL7-BAL1/ARTD9-siRNA knockdown cells upon IFN! 
stimulation (Figure 8A). The major cytoplasmic localization of BAL1/ARTD9 in the 
BBAP/DTX3L expressing SUDHL-7 cell line is in agreement with previous studies 
demonstrating that both BAL1/ARTD9 in the BBAP/DTX3L proteins are mainly 
localized in the cytoplasm and less prominent, but significantly expressed in the 
nucleus of primary HR-DLBCL (25) It has been therefore suggested that complex 
formation between BBAP/DTX3L and BAL1/ARTD9 in the nucleus could facilitate 
the nuclear export of the BAL1/ARTD9 by BBAP/DTX3L (25) and thus tightly 
regulate the nuclear function of BAL1/ARTD9 in HR-DLBCL (Fig.9A). However the 
molecular mechanism(s) underlying the observed effects remain(s) to be elucidated. 
Surprisingly, control experiments showed that BAL1/ARTD9 regulates the nuclear 
translocation or nuclear export of IRF1 in an IFN!-dependent and opposing manner 
(Fig. 9B). Constitutive ectopic expression of BAL1/ARTD9 in the macrophage-like 
lung alveolar (type-II) epithelial cell line A549, which is also used as model cell line 
for IFN-signaling, surprisingly revealed that BAL1/ARTD9 induces the expression 
 89 
and nuclear translocation of IRF1 in absence of IFN! and BBAP/DTX3L. Conversely, 
IRF1 was mainly detectable in the cytoplasm and on the periplasmatic membrane 
upon IFN! stimulation, strongly indicating that another factor such as BBAP/DTX3L 
is required for the observed BAL1/ARTD9 dependent inhibition of nuclear 
translocation of IRF1 in DLBCL (Fig. 9B). However the molecular mechanism(s) 
underlying the observed effects remain(s) to be elucidated.  
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Figure 9. BAL1/ARTD9 inhibits the nuclear translocation of tumor suppressor 
IRF1. A) Immunofluorescence microscopy and sub-cellular localization of 
endogenous IRF1 and BAL1/ARTD9 in transient siRNA-BAL1 and simock RNA 
SUDHL7 knockdown cells, in presence or absence of IFN!. (B) Immunofluorescence 
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microscopy and sub-cellular localization of endogenous IRF1 in BAL1 ectopically 
over-expressing and control A549 cell lines (co-staining using mono anti-BAL1 and 
poly anti-IRF1 antibodies). 
 
4.2.2 Lack of BAL1/ARTD9 correlates with low IRF2 nuclear expression levels 
The antitumor activity of IFN! is mainly mediated through IRF1 and blocked by IRF2 
(107, 108). IRF1 and IRF2 play antagonist roles in cancer, which is best described in 
breast cancers (180-182). In many breast cancers IRF1 is mainly inactive and 
localized in the cytoplasm, while IRF2 is highly expressed in the nucleus and 
enhances the tumor growth (107, 108, 180-182). We therefore investigated the 
potential antagonistic role of IRF1 and IRF2 in DLBCLs and could observe the same 
correlation as observed in breast cancer (Fig. 10). Lack of BAL1/ARTD9 correlates 
with low IRF2 nuclear expression levels, although the nuclear translocation of IRF2 is 
not regulated by BAL1/ARTD9 in DLBCL (Fig.10). 
 
 
Fig.10 Lack of BAL1/ARTD9 correlates with low IRF2 nuclear expression levels. 
A) Immunofluorescence microscopy and sub-cellular localization of endogenous 
IRF2 in transient si-BAL1/ARTD9-RNA and simock-RNA SUDHL7 knockdown 
cells, in presence or absence of IFN!.  
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4.2.3 Auto-Regulation of the bidirectional BAL1/BBAP promoter by positive and 
negative feedback loop mechanisms in DLBCL 
BBAP/DTX3L was originally identified as a binding partner of BAL1/ARTD9 (163). 
BBAP/DTX3L is also over-expressed in subtypes of high risk chemotherapy-resistant 
“host response” HR-DLBCL (25, 163). In order to investigate whether BAL1/ARTD9 
and BBAP/DTX3L are able to regulate each other also on the level of gene expression 
through their bidirectional BAL1/BBAP promoter we analyzed their expression levels 
in shBAL1-RNA and shBBAP-RNA SUDHL7 cell lines as well as in BAL1/ARTD9 
and BBAP ectopically expressing GCB- and ABC-DLBCL cell lines. Surprisingly 
these results revealed that BAL1/ARTD9 enhances both basal and IFN!-induced 
expression of BBAP/DTX3L and BAL2/ARTD8 in the HR-DLBCL cell line 
SUDHL7, which endogenously expresses BAL1/ARTD9 and BBAP/DTX3L. 
Conversely ectopic expression of BAL1/ARTD9 in BAL1/ARTD9-negative GCB- 
and ABC-DLBCL cell lines stimulates basal expression of BBAP/DTX3L and 
BAL2/ARTD8 while repressing the IFN!-induced expression of BBAP/DTX3L and 
BAL2/ARTD8 in these cell lines. These results strongly indicate that BAL1/ARTD9 
and BBAP/DTX3L are able to regulate each other in a cell type specific manner 
through positive and/or negative feedback loop mechanisms of auto-regulation (Fig. 
11). 
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Figure 11. mRNA expression levels analysis of BAL1/ARTD9 and BBAP/DTX3L 
by q-PCR. 
mRNA was isolated from mock,shBAL1-RNA and shBBAP-RNA expressing cell 
lines and compared with control, BAL1/ARTD9 or BBAP/DTX3L over-expressing 
cell lines. mRNA levels were measured by q-PCR and normalized against GAPDH 
and presented here as fold on the control cell lines. 
 
 
To further assess whether this regulation is occurring directly on the chromatin levels, 
we performed ChIP assays in order to test whether both BAL1/ARTD9 and 
BBAP/DTX3L are recruited to their own bidirectional promoter. Indeed, these 
experiments revealed that also BBAP/DTX3L binds its own bidirectional promoter 
leading to the conclusion that BAL1/ARTD9 strictly associates with BBAP/DTX3L 
expression levels and auto-regulates their own expression in cell type and condition 
dependent manner (Fig.12). 
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Figure 12. BBAP/DTX3L is also recruited to its own bidirectional promoter and 
associates with BBAP/DTX3L expression levels.  
 
 
4.2.4 Does BAL1/ARTD9 stimulate growth, migration and chemo- and radio-
resistance in prostate cancer? 
Recent gene expression studies have revealed that IFN signaling may play an 
important role in human prostate cancer (118, 119). For instance, 29% of clinical 
human prostate cancers analyzed, constitutively expressed STAT1 and interferon 
stimulated genes (ISGs) in vivo (118). STAT1 has been therefore suggested as a 
potential target for radio-sensitization of aggressive tumors that constitutively over-
express IFN/STAT1-dependent pathways. It has been shown that multiple small doses 
of ionizing radiation can activate an IFN (!, ", and #)-related, STAT1-dependent 
DNA damage gene expression signature (including STAT1, G1P2, G1P3, IFITM1, 
IFIT1, IRF9, MX1, HLA-C, OAS1 and OAS3) in prostate cancer (117-121). 
Moreover, in vitro selection against IFN! or IFN# and constitutive expression of 
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STAT1 leads to an IFN- and radio-resistant phenotype in prostate tumor cells (117, 
118). In addition, the IFN/STAT1 signaling pathway is also up-regulated in chemo-
resistant prostate cancer cells (118, 119). Remarkably, STAT1-dependent chemo-
resistance was also associated with increased resistance to ionizing radiation and 
accompanied by the up-regulation of ISGs that overlapped, in part, with the IFN/DNA 
damage gene expression signature (117, 118). However, the exact molecular 
mechanisms how STAT1 signaling pathways mediate chemo- and radio-resistance in 
prostate cancer remain to be elucidated. We therefore investigated whether 
BAL1/ARTD9 could play a similar role in prostate cancer, thus being at least in part 
responsible for the STAT1 mediated chemo- and radio-resistance observed in prostate 
cancer. In an initial screening done in our lab we observed that BAL1/ARTD9, 
BAL2/ARTD8 and BBAP/DTX3L, are also constitutively over-expressed in different 
metastatic prostate carcinoma cell lines, including the semi-chemoresistant, p53 
negative and androgen-refractory metastatic prostate cancer cell lines PC3 and DU145 
(183-187) (personal communications, S.B. Bachmann and P.O. Hassa). Moreover, 
both PC3 and DU145 cell lines are also associated with constitutive STAT1 signaling 
and nuclear localization of pSTAT1-S727 (Fig. 13).  
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Fig.13 PC3 cells are associated with constitutive STAT1 signaling.  
Immunofluorescence microscopy and sub-cellular localization of endogenous STAT1, 
pSTAT1-Y701 and pSTAT1-S727 in presence or absence of IFN!. 
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Our preliminary and ongoing experiments already revealed that BAL1/ARTD9 
could indeed play a similar survival related function in androgen-refractory metastatic 
prostate cancer as previously observed in chemo-resistant HR-DLBCL cells. 
Expression analysis of IRF1 in PC3-siRNA-BAL1/ARDT9 knockdown cells showed 
that IRF1 is up-regulated in absence of BAL1/ARDT9 when compared with siRNA 
mock cells (Figure 13). We next compared the phosphorylation pattern of STAT1 in 
PC3-siRNA-BAL1/ARDT9 knockdown cells and PC3-siRNA mock cells. However, 
the BAL1/ARDT9 mediated stimulation of STAT1-phosphorylation on Y701 
observed in PC3 cells is weak and not comparable with the HR-DLBCL-cell line 
SUDHL7. The observed differences between the HR-DLBCL-cell line SUDHL7 and 
the metastatic prostate carcinoma cell line PC3 could be explained by the remaining 
IFN sensitivity of PC3 and DU145 cell lines. Phosphorylation of STAT1 on both 
S727 and Y701 cannot be further stimulated with IFN# or IFN! in HR-DLBCL-
SUDHL7 cells while in the PC3 and DU145 prostate cancer cell lines phosphorylation 
of STAT1 on Y701 is still further stimulated by IFN! or IFN!. In order to test 
whether BAL1/ARDT9 has also a direct effect on cell proliferation and cell survival 
under normal growth conditions, we analyzed the proliferation of PC3-siRNA-
BAL1/ARDT9 knockdown cells and PC3-siRNA-mock cells. Remarkably, these 
experiments revealed that knockdown of endogenous BAL1/ARDT9 in the metastatic 
prostate carcinoma cell line PC3 strongly inhibits proliferation and cell survival when 
compared with control cells (Fig. 14A and B). These preliminary results already 
indicate that BAL1/ARDT9, most likely together with STAT1, could also mediate 
survival and proliferation in prostate cancer and thus, contributing to development of 
metastatic prostate cancer. 
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Figure 14. BAL1 inhibits IRF1 expression and mediate proliferation in 
metastatic prostate cancer cell line PC3. 
A) qPCR analysis of IRF1 and BAL1 gene expression in PC3-parental, simock and 
siBAL1-knock-down cells treated without or with 1000 U/ml IFN! for 8 h. B) Cell 
viability and proliferation analysis of PC3-parental, simock and siBAL1-knock-down 
cells in a time course of 96 h, was assessed by WST-1 Assay. 
 
4.2.5 ARTD/PARP inhibitors negatively affect growth and survival of DLBCL 
Many GCB and many NC DLBCL subtypes contain mutations in the PTEN gene. 
Recent studies showed that ARTD/PARP inhibitors negatively affect growth and 
survival of tumors harboring PTEN mutations (188).  Moreover the observed 
interaction between BAL1/ARTD9 and STAT1 as well as between BAL1/ARTD9 
and BAL2/ARTD8 and ARTD1, respectively, through their macro-domains seem to 
be dependent on mono-ADP-ribosylation (see result section, and personal 
communications H.C. Winkler and P.O. Hassa). These observations prompted us to 
speculate whether BAL2/ARTD8, ARTD1 or other enzymatically active ARTDs 
could be involved and also responsible for the observed effects, thus modulate 
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BAL1/ARTD9 mediated cell proliferation and survival in DLBCL. Besides inhibiting 
ARTD1 and ARTD2, DPQ, olaparib and ABT-888/veliparib can also inhibit the 
activity of BAL2/ARTD8, BAL3/ARTD7 or ARTD10, respectively (127, 172, 189). 
In order to test this hypothesis we treated different BAL1/ARTD9 non-expressing 
DLBCL cell lines and BAL1/ARTD9 expressing DLBCL cell lines with ARTD 
inhibitors. Indeed, our preliminary studies revealed that co-administration of the 
ARTD/PARP inhibitors olaparib (Astra Seneca), ABT-888 (veliparib, Abbott 
Laboratories) results in decrease of cell proliferation and increase in apoptosis in 
different DLBCL cell lines (an example is shown in Figure 15). However, no 
differences between BAL1/ARTD9 expressing and BAL1/ARTD9 non-expressing 
DLBCL cell lines could be observed under the tested conditions. Moreover, both 
PTEN wt (ABC-DLBCLs) cell lines and PTEN mutated (GCB-DLBCL) cell lines 
were negatively affected by ARTD/PARP inhibitors, indicating that neither 
BAL1/ARTD9 nor PTEN is required for the putative synthetic lethality induced by 
ARTD/PARP inhibitors in these cells. Interestingly, proliferation of Burkitt 
lymphoma cell lines (such as Ramos) seems not to be inhibited by ARTD/PARP 
inhibitors.  
 
Figure 15 ARTDs inhibitors may impair the cell growth in non-Hodgkin's 
lymphoma cells.  
Cell proliferation were analyzed using the WST-1 Assay. 
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5. DISCUSSION  
 
5.1 Summary of the results in DLBCL  
In this study, we identified BAL1/ARTD9 acting as a novel IFN!-specific 
oncogenic survival factor, which inhibits the anti-proliferative and pro-apoptotic 
activities of tumor suppressor IRF1 while simultaneously activating the BCL6-
mediated anti-apoptotic-pro-survival pathways. This study further shows that 
constitutive over-expression of BAL1/ARTD9 in DLBCL and androgen-refractory 
metastatic prostate cancer is tightly associated with constitutively active STAT1 
signaling. BAL1/ARTD9 interacts with both STAT1 isoforms, STAT1" and STAT1# 
through its macro domains and together with STAT1# acts as a transcriptional 
repressor of IRF1 expression. Moreover this study showed first time that a risk related 
protein prevents the nuclear import or enhance the export of IRF1 in DLBCL. By 
counteracting the pro-apoptotic IFN!-STAT1-IRF1 axes, BAL1/ARTD9 facilitates 
the oncogenic functions of STAT1 and explains why constitutive IFN!-STAT1 
signaling does not lead to apoptosis but rather to chemo-resistance in HR-DLBCL. 
These study also provides first evidence that BAL1/ARTD9 not only blocks IFN!-
STAT1-IRF1-mediated apoptosis and inhibition of growth, but could also enhance or 
lead to chemo-resistance in high-risk HR-DLBCL. Our observations could also 
provide a molecular mechanism for the risk-related activity of BAL1/ARTD9 in HR-
DLBCL subsets without constitutive active STAT1 signaling. IFN! induced 
expression of BAL1/ARTD9 could be directly involved in inhibiting the IFN!-
dependent host immune response against HR-DLBCL through negative feedback 
regulation of the extrinsic IFN!-induced anti-proliferative and pro-apoptotic STAT1-
IRF1 axes. Finally, the observed macro domain and mono-ADP-ribosylation-
mediated interaction between BAL1/ARTD9 and STAT1 also indicates a regulatory 
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cross talk between BAL1/ARTD9 and other active members of the ARTD family in 
this process. Finally, our preliminary analysis of p53 negative and androgen-
refractory metastatic prostate cancer cell lines already revealed that BAL1/ARTD9 
could also play a similar survival related function in metastatic prostate cancer as 
observed in chemo-resistant HR-DLBCL. However many important questions remain: 
 
5.2 Does BAL1/ARTD9 act both as a (co)activator and (co)repressor of 
IFN! /STAT1 signaling in a context dependent manner in tumorigenesis ? 
Previous studies showed that doxocyclin-induced over-expression of BAL1/ARTD9 
in BAL1/ARTD9 non-expressing low risk GCB-DLBCL cells led to the induction of 
a very small subset of IFN-related genes, mainly type I (IFN"/#)-dependent genes 
(including IRF7 or OAS1-1) (25), thus providing preliminary evidence that 
BAL1/ARTD9 might act as an IFN"/#-dependent transcriptional coactivator (25). In 
sharp contrast, our studies showed that BAL1/ARTD9 does not transcriptionally 
activate these IFN"/#-related gene cluster in HR-DLBCL, but rather directly repress 
the pro-apoptotic IFN!-STAT1-IRF-1 axes. These observed difference could be 
explained in two ways: Firstly, BAL1/ARTD9 could modulate gene expression in a 
cell type specific and context dependent manner; independent whether BAL1/ARTD9 
is constitutively expressed or induced by IFN! or IFN"/# in the corresponding cells. 
Secondly, the transcriptional activity of transiently over-expressed BAL1/ARTD9 in 
BAL1/ARTD9 non-expressing cells (i.e. induced by IFN! or IFN"/#) is different 
from that of constitutively over-expressed BAL1/ARTD9 in HR-DLBCL or 
metastatic prostate cancer cell lines. Our results, together with the published data 
would even suggest a combination of both; transiently over-expressed endogenous 
BAL1/ARTD9 could activate IFN! or IFN"#-related gene expression in non-
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expressing cells upon stimulation with IFN! or IFN"/#, while subsequently 
terminating subsets of IFN! or IFN"# dependent gene expression programs and 
signaling pathways to prevent over-activation of IFN! or IFN"# signaling and 
eventually cell death. Thus constitutively expressed BAL1/ARTD9 in high risk HR-
DLBCL and metastatic prostate cancer might just mimic in part the situation in 
primary cells under normal physiological condition and specifically terminates the 
subset of anti-proliferative and pro-apoptotic tumor suppressing IFN!-dependent 
signaling pathways. The observed repression of IRF1 through BAL1/ARTD9 might 
also represent a negative feedback loop. A previous study provided evidence that 
transcriptional activation of BAL1/ARTD9 is mainly regulated by STAT1 and IRF1 
(25).  
 
 
5.3. How does BAL1/ARTD9 regulate the kinase activities in tumorigenesis?  
Regulation of STAT1 phosphorylation is very complex. In the canonical IFN-
gamma signaling pathway, activation of STAT1 is initiated through tyrosine 
phosphorylation on Y701, a process that involves JAK tyrosine kinases JAK1/2 and 
PYK2, which belongs to another PTK family (190, 191). JAK2 is thought to 
phosphorylate STAT1 on Y701 in the cytoplasm while JAK1 seems to be required for 
phosphorylation on Y701 in the nucleus, preventing nuclear export of STAT1 (190). 
STAT1, although phosphorylated on Y701, is unable to localize in the nucleus in the 
absence of JAK1 or JAK1 kinase activity (190). For full transcriptional activity and 
biological function, STAT1 must also be phosphorylated on S727 (192-194). STAT1 
exists in two mayor isoforms, the full-length isoform STAT1", which mainly acts as a 
sequence specific activator of gene expression and STAT1#, lacking the 
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transactivation domain and acting as a sequence specific transcriptional repressor 
(192, 195, 196). STAT1 phosphorylation on Y701 and nuclear translocation are 
required for IFN-induced S727 phosphorylation in canonical signaling pathways (193, 
194). Phosphorylation on tyrosine 701 enhances the nuclear shuttling by triggering the 
nuclear retention of the shuttling of both isoforms STAT1" and #, which are kept in 
the nucleus until tyrosine dephosphorylation occurs (190, 193, 194, 197). However 
the molecular mechanisms underlying the IFN-induced S727 phosphorylation are not 
yet completely understood.  Several kinases have been suggested to phosphorylate 
STAT1 on S727 in a cell type and stimuli dependent manner (192-194, 198-204). For 
instance, the multifunctional Ca(2+)/calmodulin-dependent kinase (CaMK) II can 
interact directly with STAT1 and phosphorylate STAT1 on S727 in response to IFN-
gamma and Ca(2+) flux (199, 200). Other studies provided evidence that 
phosphorylation/activation of PKC-$ is required for phosphorylation of STAT1 on 
serine 727, as inhibition of PKC-$ activity blocks the IFN"/#-dependent serine 
phosphorylation of STAT1 and IFN"/#-inducible gene transcription (201, 202, 205). 
Furthermore, a recent study provided evidence that both the p38 mitogen-activated 
protein kinase (MAPK) and the CaMKII are activated in response to BCR signaling to 
converge on STAT1 phosphorylation on S727 for maximal gene expression (199). In 
contrast, UV irradiation-induced STAT1 phosphorylation on S727 seems to be 
exclusively p38 MAPK-dependent and independent of CaMKII or PKCs (198). More 
interestingly, recent studies found that STAT1 is constitutively phosphorylated on 
S727 in Wilms tumor by protein kinase Casein kinase (CK)-2 (203, 204). To make it 
even more complex recent studies provided evidence that nuclear translocation and 
serine phosphorylation of STAT1 on S727 can also occur independently of STAT1 
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tyrosine phosphorylation on Y701 (206). This situation is very likely the case in the 
metastatic prostate cancer cell lines PC3 and DU145. 
Our studies provided first evidence that BAL1/ARTD9 directly or indirectly 
stimulates phosphorylation of STAT1 on Y701 but not S727 in HR-DLBCL. Since 
serine phosphorylation on S727 can only take place in STAT1" but not in STAT1# 
our results indicate that BAL1/ARTD9-mediated stimulation of tyrosine 
phosphorylation on Y701 could influence the shuttling kinetics of STAT1" and 
STAT1#, thus may tipping the balance between the STAT1" and STAT1# isoforms 
in HR-DLBCL and probably also in metastatic prostate carcinoma. BAL1/ARTD9 
might therefore act as a cell and context specific regulatory factor in the fine-tuning of 
the IFN!-dependent signaling cascades. Whether BAL1/ARTD9 directly or indirectly 
regulates the corresponding kinases involved in this process remains to be elucidated. 
The observed modulation of kinase activities may also be mediated by one of the 
interaction partners of BAL1/ARTD9, such as BBAP/DTX3L or BAL2/ARTD8. 
Indeed a recent study provided first evidence that ARTD8/BAL2 promotes the 
survival of myeloma cells by binding and inhibiting the kinase activity of c-Jun N-
terminal kinase (JNK)-1 (160). Remarkably, JNK1 can also transcriptionally 
upregulate IRF1 and induce XIAP-associated factor 1 (XAF1) mediated apoptosis in 
gastrointestinal cancer (207).  
Surprisingly, siRNA mediated knock-down of BBAP/DTX3L in the metastatic 
prostate cancer cell line PC3 led to an increase of phosphorylation of STAT1 on Y701 
(personal communication SB. Bachmann and PO. Hassa), indicating that 
BBAP/DTX3L opposingly regulates the kinase activity of JAK1/2 in these cells. 
Thus, BAL1/ARTD9 together with BBAP/DTX3L and/or BAL2/ARTD8 may 
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synergistically or antagonistically regulate the phosphorylation pattern of STAT1 and 
IRF1 expression. 
 
5.4. How does BAL1/ARTD9 regulate the subcellular localization of tumor 
suppressor IRF1?  
Numerous tumor suppressors such as p53, shuttle between nucleus and cytoplasm in a 
tightly regulated fashion (208). Aberrant regulation of these processes in cancer cells 
can either inhibit export and leads to nuclear retention of the complexes or enhance 
the export of the corresponding tumor suppressor (208). Our study provides 
preliminary evidence that BAL1/ARTD9 is not only able to inhibit IRF1 on the level 
of transcriptional activation but also on the level of nuclear import or nuclear export. 
To the best of my knowledge this is the first observation that a risk related protein 
prevents the nuclear import or enhance the export of IRF1 in HR-DLBCL. However 
the molecular mechanism(s) underlying the observed IFN#-dependent inhibition of 
nuclear import or enhancement of nuclear export of IRF1 remain(s) to be elucidated. 
One possibility might be that translocation of IRF1 is negatively regulated by the E3 
ubiquitin ligase BBAP/DTX3L. BBAP/DTX3L has been previously suggested to 
regulate the sub-cellular localization of BAL1/ARTD9 (163). Complex formation 
between BBAP/DTX3L and BAL1/ARTD9 in the nucleus could facilitate the nuclear 
export of the BAL1/ARTD9 by BBAP/DTX3L (25) in HR-DLBCL. 
 
5.5. Do BAL1/ARTD9 and BBAP/DTX3L together co-regulate the expression of 
IFN!-dependent genes? 
Since BAL1/ARTD and its binding partner the E3 ubiquitin ligase BBAP/DTX3L, are 
both constitutively over-expressed in chemo-resistant HR-DLBCL and metastatic 
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prostate cancer cell lines as well as their sub-cellular localization is tightly connected 
they might also function together in regulating IFN#-dependent signaling and gene 
expression. BBAP/DTX3L and BAL1/ARTD9 have been suggested to form nuclear 
complexes (25). A recent study provided preliminary evidence that BBAP/DTX3L 
may shuttle to the nucleus in response to chemotherapy-induced DNA damage, 
selectively mono-ubiquitylate histone H4 lysine 91 and increase the protection of cells 
exposed to DNA-damaging agents (164). However the exact molecular mechanisms 
and potential connection to BAL1/ARTD remains to be elucidated. For instance, 
chemotherapy-induced DNA damage often also activates canonical and non-canonical 
IFN#-dependent signaling pathways and induces an interferon-related gene signature 
for DNA damage resistance (120). Thus, it remains to be investigated whether 
BAL1/ARTD9 could recruit BBAP/DTX3L to (mono-ADP-ribosylated?) chromatin 
and whether (subsequent?) mono-ubiquitylation on histone H4 lysine 91 by 
BBAP/DTX3L could directly positively or negatively modulate the transcriptional 
activity of STAT1 and/or BAL1/ARTD9 on promoters of IFN-target genes co-
regulated by STAT1 and BAL1/ARTD9. 
 
5.6  Are STAT1 and STAT2 mono-ADP-ribosylated in vivo? 
The observation that BAL1/ARTD9 interacts with STAT1 and STAT2 through their 
macro domains in an ADP-ribosylation dependent manner strongly indicates that the 
observed interaction depend on mono-ADP-ribosylation of STATs. Indeed, our initial 
in vitro screens showed that STAT1 could be mono-ADP-ribosylated in vitro by 
different ARTD family members, including ARTD10 (personal communication PO 
Hassa). Interestingly both BAL2/ARTD8 and ARTD10 are also constitutively 
expressed in HR-DLBCL and metastatic prostate cancer cell lines and also shuttling 
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to the nucleus in these cells  (personal communications SB Bachmann & PO. Hassa). 
However we have no evidence so far found that BAL2/ARTD8, BAL3/ARTD3 or 
ARTD10 could also mono-ADP-ribosylate STAT1 or STAT2 in vivo.  
 
5.7. Crosstalk or conditional/synthetic lethality between BAL1/ARTD9 and other 
ARTDs in tumorigenesis? 
Both BAL1/ARTD9 and BAL2/ARTD8 not only interact through their macro-
domains with STAT1, STAT2 (see result section) or STAT6 (132, 152) respectively, 
but also interact with other ARTD members such as ARTD1 and ARDT10 (personal 
communications H.C. Winkler and P.O. Hassa). Moreover, all three B-agressive 
lymphoma protein and macro-domain containing ARTDs BAL1/ARTD9, 
BAL2/ARTD8 and BAL3/ARTD7 can interact with each other through their macro-
domains, (personal communications H.C. Winkler and P.O. Hassa). Interestingly, 
subsequent analysis revealed that the observed interactions are most likely dependent 
on (n)ADP-ribosylation (personal communications H.C. Winkler and P.O. Hassa).  
ARTD1 plays an important role as a tumor promoting factor in tumorigenesis (125). 
ARTD10 (former PARP10) has been initially identified as a novel c-Myc-interacting 
mono-ADP-ribosyltransferase that inhibits c-Myc- and E1A-mediated transformation 
(209). These preliminary results suggest a potential functional crosstalk among the B-
aggressive lymphoma protein and macro domain containing ARTD family member 
BAL1/ARTD9, BAL2/ARTD8 and/or BAL3/ARTD7 and more interestingly between 
BAL1/ARTD9 and ARTD1. Indeed, our preliminary studies revealed that the 
ARTD/PARP inhibitors such as olaparib and ABT-888/veliparib, negatively affect 
cell proliferation and survival in different DLBCL cells. Remarkably the observed 
effects seems to be independent of any DNA repair deficiency in these cells since 
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both PTEN wt (ABC-DLBCLs) cell lines as well as PTEN mutated (GCB-DLBCL) 
cell lines were negatively affected by ARTD/PARP inhibitors.  
On the other hand one has to be very cautious since no differences between 
BAL1/ARTD9 expressing and BAL1/ARTD9 non-expressing DLBCL cell lines 
could be observed under the tested conditions, indicating that neither BAL1/ARTD9 
nor PTEN is required for the putative synthetic lethality induced by ARTD/PARP 
inhibitors in these cells. However these results suggest, at least in part, that a potential 
crosstalk among ARTDs could be the target of ARTD/PARP inhibitors in DLBCL 
cell lines. On the other hand since several recent studies clearly demonstrated that 
many ARTD/PARP inhibitors not only negatively affect the activities of most ARTD 
family members but also inhibit ARTD non-related enzymes such as the IFN/STAT1 
dependent oncogenes and serine/threonine kinases PIM1 and PIM2 (210) it is difficult 
to speculate about the molecular mechanism underlying our preliminary observations. 
Remarkably, PIM kinase inhibition has been already proposed as a rational approach 
in lymphoma treatment (211). For instance, PIM1 is also over-expressed in GCB-
DLBCL and cooperates with human BCL6 to promote the development of GCB-
DLBCL (212). PIM2 over-expression has been also detected in subsets of mantle cell 
lymphoma, ABC-DLBCL, follicular lymphoma, marginal zone lymphoma-mucosa-
associated lymphoid tissue type, chronic lymphocytic leukemia, and nodal marginal 
zone lymphoma cases (213, 214). PIM2 protein expression is also associated with an 
aggressive clinical course in ABC-DLBCL (213, 214). Thus, PIM1 and PIM2 kinase 
inhibition has been suggested to be a promising therapy for BCL6/PIM1-positive 
human GCB-DLBCL and PIM2-positive ABC-DLBCL, respectively (211-214). 
Future studies using a panel of single and double si/shRNA knockdown cells or novel 
highly-specific ARTD/PARP and JAK/STAT1 inhibitors with less or only few off 
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target effects will certainly give us more insight into the potential functional crosstalk 
between BAL1/ARTD9 and other ARTD family members in HR-DLBCL and other 
cancer types. 
 
 
PERSPECTIVES 
6.1. What are the functional roles of BAL1/ARTD9 under normal physiological 
conditions? 
One of the most intriguing questions is how BAL1/ARTD9 could regulate IFN# or 
IFN!/" dependent genes under normal physiological conditions. Mice models are one 
of the best approaches for analyzing the biological functions of a given gene product 
of interest. Several mice models for mono-ADP-ribosylating ARTD family members 
have been already established, including knockout mice of BAL2/ARTD8 and 
ARTD14/TiPARP (158, 215). However, no mice models for BAL1/ARTD9 are yet 
available, thus we can only speculate about the physiological roles of BAL1/ARTD9 
in vivo. Interestingly, mice models for BAL2/ARTD8 already suggest that the macro 
domain containing ARTDs may play fundamental roles under normal physiological 
conditions. Several recent studies using BAL2/ARTD8 KO mice models provided 
first evidence that BAL2/ARTD8 regulates IL4 induced cell survival and proliferation 
of B cells, cytokine-regulated metabolic activity in B-cells as well as TH2 
differentiation (152, 158, 216). 
All three B-aggressive lymphoma protein and macro domain containing ARTDs 
BAL1/ARTD9, BAL2/ARTD8, BAL3/ARTD7 and their binding partner, 
BBAP/DTX3L are highly inducible proteins and only constitutively expressed in vivo 
at extremely low levels in lymphocyte-rich tissues (153). Expression of 
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BAL1/ARTD9, BAL2/ARTD8, BAL3/ARTD7 and BBAP/DTX3L is highly induced 
upon stimulation with IFN!, IFN"/#, LPS  (an example is shown in fig. 17) or upon 
infection with H. pylori, S. typhimurium and various RNA viruses (153-157). Thus 
BAL1/ARTD9 might also play important roles under normal physiological conditions 
(i.e. during cell differentiation) or in innate immunity. Moreover, since both 
BAL1/ARTD9 and BAL2/ARTD8 are acting as co-regulator of STAT1 (these study) 
and STAT6 (132, 152), respectively, IL-4, IFN# and/or IFN!/"-dependent signaling 
pathways could be synergistically or antagonistically co-regulated by BAL1/ARTD9 
and BAL2/ARTD8.  
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Figure 17. Relative mRNA expression levels of BAL1/ARTD9 in primary 
PBMCs and Raw 264.7 macrophages upon stimulation with IFN!  or LPS. 
mRNAs were isolated from primary peripheral blood mononuclear cells (A) and 
RAW-264.7 cells (B) treated with or without IFNg (10ng/mL) in a time frame of 36 h 
(A) and 1h LPS (100ng/ml) stimuli (B). mRNAs levels of IFNs responsive genes were 
analyzed by qPCR and normalized against GAPDH.  
 
 
6.2 Potential functional roles of BAL1/ARTD9 in innate immunity  
Several studies have been recently shown that several ARTD family members,  
including ARTD3, BAL1/ARTD9, BAL2/ARTD8, ARTD10, ARTD11, ARTD12 
and ZAP/ARTD13 are upregulated along BBAP/DTX3L, STAT1, OAS1-1, IRF1, 
IRF2, IRF7 and MX1 upon infection with bacterial and viral pathogens (154-157, 
217). Moreover, three members of the WWE domain containing ARTD subgroup, 
namely ARTD11 and the zinc finger containing ZC3HDC1/ARTD12 and 
ZC3HAV1/ARTD13 have been recently identified as host factors with broad antiviral 
activities (156, 157). The exact molecular mechanisms underlying the antiviral 
activity of ARTD11 and ARTD12 are not yet known while the antiviral activities of 
ARTD13 are well investigated (218-221). ARTD13 directly interferes at multiple 
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levels with the replication of several important human RNA viruses, including SARS, 
influenza virus and human HIV-1 (218-221). For instance, ARTD13 can detect viral 
RNA and activates both the exosome-mediated RNA degradation pathway as well as 
RNA helicase RIG-I induced signaling cascades (218-223). Remarkably, most of the 
novel antiviral factors identified in the recent screening studies did only moderately 
inhibit the viruses when expressed individually (156, 157, 222). For instance 
ARTD11, ARTD12 and ZAP/ARTD13 showed only 20-30 % inhibition while the 
well-known antiviral genes, such as ISG20, MX2, IRF1, and OAS1-1 showed strong 
inhibition between 80-95% (157, 222). It has been already previously shown that 
expression of various combinations of antiviral factors have an additive inhibitory 
effect on viruses (156).  
The observations that BAL1/ARTD9 interacts with ARTD11, ARTD12 and 
ZAP/ARTD13 (personal communications HC Winkler and PO Hassa) suggest that 
BAL1/ARTD9 might negatively or positively interfere with RNA virus replication or 
in general with the life cycle of RNA viruses. Moreover, BAL1/ARTD9 can also 
transcriptionally upregulate ARTD3, ARTD11, ARTD12 and ZAP/ARTD13 
independent of IFN# (an example is shown in Fig. 18). BAL1/ARTD9 and 
BBAP/DTX3L could act in combination with ZAP/ARTD13 as IFN# and/or IFN!/" 
dependent antiviral factors. BAL1/ARTD9 could be required for terminating the IFN# 
or IFN-!/" response upon infection with viral or bacterial pathogens.  The regulation 
of IFN# and IFN-!/" response must be tightly coordinated to maintain appropriate and 
timely immune reactions (224). Without mechanisms that shut down prolonged, 
inappropriate or excessive immune response and inflammation, the organism would 
die from damage caused by these viral or bacterial pathogens. Both pro- and anti-
inflammatory signaling networks must be activated and balanced for an organism to 
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survive in the face of an infection with viral and/or bacterial pathogens that elicit an 
immune response (224). Therefore, BAL1/ARTD9 could not only co-activate the 
initial IFN# and IFN!/" response as transcriptional co-activator but also subsequently 
or simultaneously inhibit the pathogen-induced IFN# and/or IFN!/" dependent pro-
apoptotic signaling pathways. Interestingly, most RNA virus induces cell death in 
order to further infect the surrounding tissues.  
 
Figure 18. ARTD9/BAL1 enhances the mRNAs levels of others ARTDs with a 
known antiviral activity  
mRNAs were isolated from BAL1/ARTD9 ectopically over-expressing and control 
(mock) cell lines treated with or without IFN# (10ng/mL) ARTD genes were analyzed 
by qPCR and normalized against GAPDH.  
 
 
 
6.3 Does BAL1/ARTD9 act as a regulator of STAT1-non-related signaling 
pathways? 
The observation that expression of BAL1/ARTD9, BAL2/ARTD8, BAL3/ARTD7 
and BBAP/DTX3L is highly induced upon stimulation with LPS or upon infection 
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with viral and bacterial pathogens suggests that BAL1/ARTD9 might also function as 
a regulator of STAT1 non-related signaling pathways such as NF-%B-dependent 
signaling. Moreover, interaction screen performed in the Hassa lab identified several 
NF-%B-dependent signaling related interaction partners of BAL1/ARTD9 involved in 
innate immunity, including p62/sequestosome. p62/sequestosome has been shown to 
play a central regulatory role in NF-%B related inflammation processes due to its 
modulator function in autophagy and as a crucial regulator and interaction partner of 
the atypical PKC kinases (225-228). Unfortunately initial gene expression screens did 
not reveal any NF-%B related co-activator or co-repressor function for BAL1/ARTD9 
under the tested conditions (personal communication PO. Hassa), thus not supporting 
this hypothesis. On the other recent screens in the Hassa and Richards labs (CABMM 
UZH) using different in vitro models of STAT1/IFN# and/or NF-%B-dependent 
mesenchymal stem cell (MSC) differentiation revealed a potential function of 
BAL1/ARTD9 in differentiation processes. STAT1 plays together with NF-%B, a 
critical regulatory role in both osteoclastogenesis and osteoblastogenesis (229-233). 
For instance, STAT1/IFN# has been reported to act as a potent inhibitor of 
osteoclastogenesis while concomitantly induce osteoblastogenesis from MSCs both in 
vitro and in vivo, thereby modulating the balance between osteoclasts and osteoblasts 
in vivo (229-231, 234). No clear effect of STAT1 or IFN# on adipogenesis has been 
so far reported. NF-%B-dependent signaling has STAT1/IFN#-opposing effects in 
osteoclastogenesis and osteoblastogenesis (232, 233) while adipogenesis is inhibited 
by elevated NF-%B activity (235). Thus, osteoclastogenesis, osteoblastogenesis and 
adipogenesis from MSCs serves as a suitable in vitro model for investigating the 
potential functions of BAL1/ARTD9 in STAT1/IFN#-dependent and independent cell 
differentiation processes.  
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Remarkably, these preliminary and ongoing studies already revealed that 
BAL1/ARTD9 might indeed act as a novel IFN# and/or IFN!/" independent regulator 
of adipogenesis. Knockdown of BAL1/ARTD9 in human MSCs greatly enhanced 
adipogenesis (personal communications P.O. Hassa and A. Tiaden (CABMM, UZH)). 
Surprisingly, no effects were observed in osteoclastogenesis and osteoblastogenesis. 
Moreover, the observed effect in adipogenesis was not dependent on IFN# and/or 
IFN!/" signaling (personal communications PO. Hassa and A. Tiaden (CABMM, 
UZH)). In contrary, the repressory activity of BAL1/ARTD9 strongly correlated with 
STAT5/Smad1/3 activities indicating that BAL1/ARTD9 might functionally interact 
or modulate the TGF"-STAT5-SMAD1/3 signaling axes in adipogenesis (personal 
communications PO. Hassa and A. Tiaden (CABMM, UZH)). 
 
6.4 Conclusions 
This study identifies BAL1/ARTD9 as a novel IFN!-specific oncogenic survival 
factor, which inhibits the anti-proliferative and pro-apoptotic activities of tumor 
suppressor IRF1 while simultaneously activating the BCL6-mediated anti-apoptotic-
pro-survival pathways. Thus, by counteracting the pro-apoptotic IFN!-STAT1-IRF1 
axes, BAL1/ARTD9 facilitates the oncogenic functions of STAT1 and explains why 
constitutive IFN!-STAT1 signaling does not lead to apoptosis but rather to chemo-
resistance in HR-DLBCL and metastatic prostate cancer. In addition, our observations 
could also provide a molecular mechanism for the risk-related activity of 
BAL1/ARTD9 in HR-DLBCL subsets without constitutive active STAT1 signaling. 
BAL1/ARTD9 could be directly involved in inhibiting the IFN!-dependent host 
immune response against HR-DLBCL through negative regulation of the extrinsic 
IFN!-induced anti-proliferative and pro-apoptotic STAT1-IRF1 axes. Our 
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observations could also provide a molecular mechanism for the proposed activity of 
BAL1/ARTD9 in editing or inhibiting the IFN!-dependent host immune response 
against HR-DLBCL (as previously suggested (25, 55, 89)), through negative 
regulation of the anti-proliferative and pro-apoptotic IFN!-STAT1-IRF1 axes.  
The observed macro domain and mono-ADP-ribosylation-mediated interaction 
between BAL1/ARTD9 and STAT1 also indicates a regulatory cross talk between 
BAL1/ARTD9 and other active members of the ARTD family in this process thus, 
could provide the rational base for the development of novel BAL1/ARTD9- and/or 
ARTD family member-specific inhibitors and activators, targeting either the catalytic 
domain or macro domains in HR-DLBCL. The combination of highly specific ARTD 
inhibitors with drugs targeting specifically STAT1 or the macro domains of 
BAL1/ARTD1 might be a strategy to increase the sensitivity of HR-DLBCL towards 
classical therapy, and thus pave the way to develop novel therapeutic strategies for the 
remainder of DLBCL patients suffering from aggressive chemo-resistant high-risk 
host response variants of DLBCL and chemo-resistant metastatic prostate cancers. 
Finally, this study provides first insight how BAL1/ARTD9 may function 
under normal physiological condition in IFN!-STAT1 dependent and independent 
processes, such as innate immunity against RNA viruses. 
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